



BIOPHARMACEUTICS AND MICROBIAL PERSPECTIVES IN PHARMACEUTICAL TECHNOLOGY

Editor: Assoc Prof. Dr. İsmail ASLAN



**BIOPHARMACEUTICS AND
MICROBIAL PERSPECTIVES IN
PHARMACEUTICAL TECHNOLOGY**

Editor: Assoc Prof. Dr. İsmail ASLAN



Biopharmaceutics and Microbial Perspectives in Pharmaceutical Technology

Editor: Assoc. Prof. Dr. İsmail ASLAN

Editor in chief: Berkan Balpetek

Cover and Page Design: Duvar Design

Printing : March-2025

Publisher Certificate No: 49837

ISBN: 978-625-5551-76-4

© Duvar Yayınları
853 Sokak No:13 P.10 Kemeraltı-Konak/İzmir
Tel: 0 232 484 88 68

www.duvaryayinlari.com

duvarkitabevi@gmail.com

**The publisher and editors are not obligated to accept responsibility for the views, opinions, and potential ethical violations stated by the authors. The responsibility for the content in the book lies solely with the author(s).*

TABLE OF CONTENTS

Chapter 11

Microbiological Analysis and Methods in Cosmetic Products

Bashar IBRAHIM, Duygu TÜRKmen

Chapter 221

Microbiological Analysis and Methods in Medicine and Cosmetics

Bashar IBRAHIM, İsmail ASLAN

Chapter 333

Microbial Safety of Biopharmaceutical Products

Bashar IBRAHIM, Buse ZEREN

Chapter 443

Microbial Metabolism and Drug Interactions

Bashar IBRAHIM

Chapter 562

Design and Analysis of Bioavailability/Bioequivalence Studies

Ahmet Arif KURT

Chapter 672

Biopharmaceutical Classification System (BCS):

Basic Principles, Application to Cancer Drugs, and the Role of Microorganisms in BCS Assessment

Ahmet Arif KURT, Buse ZEREN, Duygu TÜRKmen, Bashar IBRAHIM

Chapter 1

Microbiological Analysis and Methods in Cosmetic Products

Bashar IBRAHIM¹

Duygu TÜRKMEN²

Abstract

Cosmetic products include a variety of preparations applied to the skin, hair, nails, and other external surfaces. They serve purposes such as cleansing, beautifying, altering appearance, and providing protection. These products often contain water, oil, proteins, carbohydrates, and other organic components, which create an environment conducive to the growth of many microorganisms. As a result, these products are vulnerable to microbial contamination, which can lead to significant damage, product deterioration, and reduced effectiveness. More importantly, this contamination poses health risks to consumers. Therefore, microbiological analyses are crucial for ensuring the safety and quality of cosmetic products. This section highlights the importance, methods, and evaluation criteria for microbiological analyses conducted on cosmetic products.

Keywords: Cosmetic products, Microbiological analysis, Microbial contamination, Safety and Quality

¹ Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Süleyman Demirel University, Isparta 23000 Turkiye. basharibrahim@sdu.edu.tr ORCID No: 0000-0003-3086-0995

² duyguturkmen6420@gmail.com ORCID No: 0009-0008-5395-1236

1. Introduction

Since its inception, the demand for cosmetics has significantly influenced an individual's health and well-being. Cosmetics are vital for personal care, hygiene, and self-esteem, thereby enhancing both social interactions and psychological wellness. Due to microbiological contamination, cosmetic products may pose an invisible and potentially deadly risk. This type of contamination not only threatens the quality of cosmetic products but also poses significant dangers to public health and safety. Metin girmek için buraya tiklayın veya dokunun.. Cosmetic products are at risk of microbiological contamination, which can compromise their effectiveness and jeopardize consumer health. This type of contamination can lead to stability issues, affecting the physicochemical properties of the products, such as color, viscosity, and phase separation (Lundov et al., 2009). Moreover, extracellular enzymes released by microorganisms, such as proteases and lipases, can chemically degrade active ingredients, leading to a significant reduction in the therapeutic or cosmetic effectiveness of the product (Fouad et al., 2023).

The levels of active ingredients decline over time, which can result in adverse reactions and the formation of potentially toxic metabolites. Thus, ensuring the microbiological safety of cosmetic products is crucial for both product quality and consumer safety. Metin girmek için buraya tiklayın veya dokunun. Microbiological contamination poses serious health risks to consumers, potentially leading to infections, allergic reactions, and other adverse effects. This underscores the critical importance of ensuring microbial safety and control in cosmetic products. Metin girmek için buraya tiklayın veya dokunun. Additionally, microbiological contamination in cosmetic products can cause skin irritations, acne, fungal infections, and allergic dermatitis. Products used around the eyes, such as mascara and eyeliner, may lead to eye infections. Metin girmek için buraya tiklayın veya dokunun. Ensuring the microbiological quality of cosmetic products is crucial for their safety and effectiveness, as well as for commercial and legal reasons. Effective microbial control protects consumer health, helps companies maintain their reputation, ensures compliance with relevant regulations, and boosts consumer confidence (Alshehrei, 2024). Microbiological contamination-related product recalls can lead to significant financial losses for companies and severely harm their brand image.

Moreover, insufficient microbial control may result in legal repercussions that range from fines to the suspension or revocation of business licenses (Patel et al., 2024). Microbiological quality control in the cosmetic industry should be regarded as a fundamental component of an integrated risk management

strategy. Microbiological contamination can arise from various sources, ranging from the formulation of pharmaceutical and cosmetic products to the end-user process. Potential risks of contamination include raw materials, water systems, equipment, packaging materials, and even production personnel and their surroundings. In this context, microorganisms that contaminate products can lead to serious health issues such as skin infections, allergic reactions, eye infections, systemic infections, and in extreme cases, even death. Contaminated microorganisms can alter a product's physical, chemical, and therapeutic properties, reduce its efficacy, produce toxic substances, and ultimately render the products ineffective. Therefore, addressing microbiological contamination is crucial for maintaining health and safety in the cosmetic industry (Alnuqaydan, 2024; Dao et al., 2018; Halla et al., 2018).

The Draft Text of the Cosmetic Products Regulation Amendment, dated April 19, 2021, has been published by the Turkish Medicines and Medical Devices Agency, which is a part of the Ministry of Health of the Republic of Turkey. According to this document, cosmetic products are categorized into several general headings, including: skincare products, skin cleansing products, body hair removal products, body hair bleaching products, products for regulating body odor and sweating, shaving and pre-shave/after-shaving products, make-up products, perfumes, sunscreen products and sunless tanning products, other skin products, hair and scalp care and cleaning products, products used for hair coloring, hair styling products, other hair and scalp products, nail polish and polish remover, products for nail care, nail strengthening products, nail adhesive remover, other nail and cuticle products, dental care products, mouthwashes, mouth sprays, teeth whiteners and other oral hygiene products. This classification provides a comprehensive overview of the various types of cosmetic products regulated under this amendment (Aras et al., 2022).

This section highlights the importance, methods, and evaluation criteria of microbiological analyses performed on cosmetic products.

2. Microbial Contamination Sources and Risks

2.1. Contamination from Raw Materials

Natural source ingredients (water, plant extracts, animal derivatives, and mineral-based substances) in the formulation of cosmetic products are a major concern for product safety and consumer health due to the environmental conditions in which natural raw materials are obtained and processed, which lead to enhanced microbial load levels. This requires control of the raw material supply chain, appropriate sanitation practices, and the use of effective

antimicrobial protection strategies. Otherwise, products can become unstable, lose their effectiveness and, worst of all, pose a health risk to consumers prone to skin infections or allergies due to microbial growth in the products (Sawicka et al., 2016).

2.2. Waterborne Contamination

Water is an essential component in nearly all cosmetic formulations and creates a favorable environment for various microorganisms. Raw water sources may harbor a range of microorganisms, including bacteria, fungi, algae, and protozoa. These microorganisms not only pose a risk to consumer health by producing toxins but can also lead to product spoilage. Additionally, water sources can easily become contaminated with opportunistic pathogens, particularly *Pseudomonas aeruginosa* (Gupta et al., 2019).

2.3. Contamination from Herbal Extracts

Plant extracts are used in cosmetic products for a variety of purposes, including antioxidant, anti-inflammatory and moisturizing agents (Kurt et al. 2024, Ibrahim et al. 2024, Kurt et al., 2024). However, these plant materials carry the risk of contamination with microorganisms from soil, air, and water during harvesting, processing, and storage. Microorganisms such as bacteria, fungi, and mold can degrade the structure of plant extracts and reduce the effectiveness of the product. In addition, some microorganisms can cause allergic reactions or irritation (Bolouri et al., 2022).

2.4. Contamination from Animal Products

Animal-derived ingredients (collagen, lanolin, beeswax) commonly used in cosmetic formulations are identified as the main risk factors for potential microbial contamination, as these ingredients are derived from skin, fur, or glands, and can be contaminated with environmental microorganisms (bacteria, fungi, viruses) from animal sources during the extraction process. That is production processes carried out under inadequate hygienic conditions and/or inadequate sterilization practices can lead to the transfer of potential pathogens to the final cosmetic product, which poses serious risks to the health of the consumer. Therefore, monitoring the supply chain of animal-derived raw materials, sterilizing the materials used in the process by reliable and validated means, and monitoring the microbial load of the final product must be strictly implemented to ensure product safety and protect public health (Cristiano et al., 2022).

2.5. Contamination from Minerals

Mineral-based raw materials such as bentonite clay and talc are frequently used in cosmetic formulations as fillers, absorbents, or coloring agents. Their natural origin makes them susceptible to microbial contamination. These minerals, obtained from the soil, may be contaminated with many microorganisms (bacteria, fungi, molds, spores) in their natural environment. Poor sanitation and sterilization conditions during the extraction, processing, and purification stages may lead to contamination with these microorganisms, which may be transferred to the final product or multiply in it. This may lead to deterioration of the microbial quality of cosmetic products. Such contamination may have significant consequences on the stability and efficacy of the final product and may pose potential health risks for consumers. To overcome this problem, strict hygiene measures, appropriate sterilization methods, and routine microbial controls are required during the processing of mineral-based raw materials (Sarruf et al., 2024).

2.6. Methods to Prevent Contamination From Raw Materials

Food safety is an integral part of management systems and should be addressed in a risk-based manner. In this perspective, supply chain management must be reliable, raw materials comply with the specifications provided, storage and processing conditions must be defined by regular laboratory analyses, sterilization/disinfection methods must be verified, personnel must be trained in hygiene, and traceability systems must be established.

3. Contamination From the Manufacturing Process

There is a strong correlation between the composition of cosmetic products and the microbiological load that may be present throughout the manufacturing process. This is because all elements in the production environment can play a role in microbial contamination. These combined effects can lead to contamination with various microorganisms (bacteria, fungi, molds) that can compromise the stability, safety, and efficacy of the product; in this scenario, strict hygiene standards and Good Manufacturing Practices (GMP) must be applied (Kim et al., 2020).

3.1. Contamination From Equipment

Heavy pharmaceutical processing equipment, mixers, filling units, pipelines, etc., represent situations where the surface properties of materials used in the manufacturing process, which go hand in hand with the processes in which certain materials are transformed, become significant risk points for microbial

cross-contamination. In the absence of appropriate cleaning and sanitization protocols, microorganisms can attach to these surfaces, grow, and develop into resistant structures known as biofilms. Biofilms cause microorganisms to become much more resistant to antimicrobial agents, making routine cleaning and disinfection processes much less effective and providing a constant source of re-contamination. Such a scenario can ultimately affect the microbial quality of products, pose significant risks to consumer health, shorten the shelf life of products, and compromise formulation stability. Therefore, it becomes imperative to adopt validated protocols that can prevent biofilm formation and are routinely used for equipment cleaning and sanitization in cosmetic manufacturing facilities, thus ensuring product quality and Safety (Kim et al., 2020).

3.2. Airborne Contamination

The air in the environment where cosmetic products are manufactured should be considered as an important vector of microbial contamination; because airflow can be directly carried out of an area and carries a range of microorganisms such as dust, pollen and bacteria, fungi, and mold originating from human activities. Microorganisms can spread to the environment and products due to open production containers, ventilation ducts without adequate filtration systems, and air currents generated by workers' movements. Airborne contamination is especially dangerous for sterile or low microbial load products; this can lead to problems such as product stability being compromised, shelf life being shortened, and most importantly consumer safety. Therefore, the implementation of appropriate ventilation designs with HEPA filters in cosmetic manufacturing facilities, continuous air quality monitoring, limited access to the production area, and effective and appropriate sanitation procedures are vital measures to reduce the possibility of aerosols contaminating the product and its Safety (Brown et al., 2013).

3.3. Methods to Prevent Contamination Originating From The Manufacturing Process

A series of comprehensive control methods must be adopted to reduce the possibility of microbial contamination in the cosmetic manufacturing process and to ensure product safety. These controls are designed in line with the principles of Good Manufacturing Practices (GMP) and are targeted at possible sources of contamination at each stage of the manufacturing process.

Basic control approaches:

- Validated cleaning and sanitation procedures for routine disinfection of production equipment.
- Training of production personnel in hygiene and use of appropriate personal protective equipment (PPE).
- HEPA filters to provide a closed-quality environment for the production environment.
- Confirmation of water quality within pharmaceutical quality standards.
- Aseptic filling/packaging guidelines, especially for sterile products.

The critical importance and continuous monitoring of these control methods are essential to ensure the microbial quality of cosmetic products and to protect consumer health (Halla et al., 2018).

4. Contamination From Packaging

While cosmetic product packaging serves vital functions such as protecting the formulation from external conditions, facilitating easy transportation, and providing a user interface that makes it practical for the consumer to use the product, packaging materials, and manufacturing processes can be potential sources of microbial contamination of the product. The risk of contamination due to microbial contamination is widespread during the production, processing, and storage stages of packaging materials such as plastic, glass, metal, or paper; in addition, the use of recycled materials further increases this risk. Factors such as cutting, shaping, and assembly of packaging materials in packaging manufacturing processes can also add contamination by microorganisms to the packaging surface when not carried out under hygienic conditions. This situation requires potential preventive measures, including cleaning or disinfection of packaging elements, the use of rake-filling methods, and the selection of multilayer packaging with microbial barrier properties. Similarly, the selection of materials compatible with the product in the protection plays an important role in reducing the risk of possible microbial contamination (Ibrahim et al., 2022).

4.1. Methods To Prevent Contamination From Packaging

The determination and control of each critical step takes place at this stage, as several control mechanisms must be planned to avoid unwanted microbial risks and maintain product integrity, up to the point of product packaging. Control mechanisms begin with the selection of appropriate packaging materials; the packaging material must be compatible with the product formulation, have low permeability or microbial barrier properties. A

comprehensive assessment of the packaging material capable of preventing the entry of potential contaminants and the potential for the packaging material to interact with the product must be made. It is very important to make the packaging material clean and sterile, especially for sterile products, and this should be done with appropriate methods (such as gamma irradiation, ethylene oxide sterilization). Aseptic filling methods guarantee that the product will be transferred to the packaging without contamination, and protective caps, seals and leakage tests that protect the integrity of the packaging ensure that the product will be protected against microbial contamination throughout its shelf life. The careful implementation of these control measures is important for preserving the microbiological quality of cosmetic products and protecting consumer health (Catovic et al., 2020).

5. Consumer-Related Contamination During Use

There is a risk of contamination with microorganisms from a bacteriological perspective due to consumer habits; these risks are greatly increased especially for products in multi-use packaging. The reason behind this is that microorganisms (including bacteria and fungi) can be transferred from skin flora or the environment to the product due to direct contact between consumers' fingers and the products. Regular cleaning practices are essential to preserve the integrity of cosmetic products and prevent potential health risks. Make-up brushes, sponges, and similar applicators become surfaces that are susceptible to microbial contamination during use. If such tools are not cleaned periodically, pathogenic microorganisms may multiply and transfer to cosmetic products. This may damage the chemical structure of the products, reduce their effectiveness, and pave the way for skin infections and other dermatological problems. Therefore, ensuring the hygienic use of cosmetic products is critical for individual health and product performance. Diluting or mixing products with saliva, water or other products can create favorable conditions for microbial growth and increase the risk of contamination. Therefore, educating consumers on hygienic practices such as washing hands before using the product, cleaning the applicator regularly, not sharing products with others, and using products under appropriate conditions is very important to maintain the microbial safety of products. Additionally, using single-use packaging and designing packaging to reduce contamination is one of the most recognized strategies for reducing the risk of consumer-related contamination (Bradley et al., 2023; Rocca et al., 2022).

5.1. Methods To Prevent Consumer Contamination During Use

Avoid Application Directly (AAD) can be a useful tool to minimize user microbial exposure during the use phase. This strategy is based on the principle of detailed information and education of consumers. In this context, consumers should be informed about the correct use of products, hygiene practices (e.g. washing hands properly before touching products, regular cleaning and disinfection of applicators), not sharing products with other users, appropriate storage conditions (stored in a cool, dry place and away from direct sunlight) and expiration dates. In addition, single-use packaging should be encouraged and product formulations that minimize the risk of contamination due to consumer error should be used. These changes can increase the microbial safety of cosmetic products and reduce potential health hazards through better awareness and hygienic practices. In such a case, manufacturers must provide clear and understandable instructions on labels, create educational materials, and regularly update consumers through available channels (websites, social media, etc.) (Halla et al., 2018; Yazici et al., 2023).

6. Microorganisms Encountered in Cosmetic Products

These types of microorganisms can range from those commonly found in cosmetic products (which vary depending on product formulation, production conditions, packaging, and personal usage habits). These are microorganisms that can cause products to deteriorate, reduce their effectiveness, and even be harmful to the health of users (Poddebnia et al., 2024). Some of the most common microorganisms found in cosmetic products.

6.1. Bacteria

6.1.1. *Pseudomonas aeruginosa*

A gram-negative bacterium, *P. aeruginosa* is a highly resistant microorganism frequently encountered in cosmetic products. Thanks to its ability to grow in a wide pH range and at different temperatures, it can easily multiply in water-based products, especially lotions, creams, and eye makeup products. *P. aeruginosa* contamination can lead to skin infections, eye infections (keratitis), and even more serious infections in people with weakened immune systems (Poddebnia et al., 2024)

6.1.2. *Staphylococcus aureus*

A Gram-positive bacterium found on human skin and nasal mucosa. Dermatitis occurs due to inadequate hygiene standards in the production of cosmetic products or improper use of these cosmetic products. *S. aureus*

infection can cause skin infections (impetigo and folliculitis), wound infections and also toxic shock syndrome. The risk is even higher with products applied to open wounds or damaged skin (Dao et al., 2018).

6.1.3. *Escherichia coli*

A Gram-negative bacterium that is often used as an indicator of fecal contamination. Detection of *E. coli* in cosmetic products is an indication of poor hygiene during production or use of contaminated water sources. *E. coli* bacteria can cause skin infections, urinary tract infections, and digestive system disorders (Dao et al., 2018).

6.1.4. *Enterobacter gergoviae*

A Gram-negative bacterium, *E. gergoviae* is commonly found in soil, water, and plants. It can contaminate cosmetic products, especially those containing water and products containing natural ingredients. *E. gergoviae* infection can cause skin and eye infections and more serious infections in people with compromised immune systems (Dao et al., 2018).

6.1.5. Fungi

Mold Fungi (Aspergillus, Penicillium, Cladosporium): Mold fungi are commonly found in the air, soil, and organic matter. They can cause contamination in cosmetic products, especially in products with natural ingredients and damaged packaging. Mold fungi contamination can lead to allergic reactions, skin irritation, and respiratory problems. In addition, some mold fungi can produce toxic substances called mycotoxins, which can be absorbed through the skin and cause health problems (Dao et al., 2018; Yadav et al., 2023).

6.1.6. Yeast Fungi (*Candida, Saccharomyces*)

Yeast fungi are naturally found in the human body (skin, mouth, intestines). However, they can cause contamination if they grow excessively in cosmetic products. Yeast fungi contamination can lead to skin infections (candidiasis), vaginal infections and more serious infections in people with weak immune systems (Yadav et al., 2023).

6.2. Other Microorganisms

6.2.1. *Acinetobacter*

A Gram-negative bacterium, is commonly found in soil and water. It can cause contamination in cosmetic products, especially water-based products, and

products manufactured in hospital environments. *Acinetobacter* contamination can lead to skin infections, wound infections, and more serious infections in people with weakened immune systems (Dao et al., 2018).

6.2.2. *Burkholderia cepacia*

The Gram-negative bacterial complex is widely found in soil, water, and plants. It can cause contamination in cosmetic products, especially water-based products and products used by patients with cystic fibrosis. Its contamination can lead to lung infections, skin infections, and more serious infections in people with weakened immune systems (Dao et al., 2018).

The presence of these microorganisms in cosmetic products not only reduces the quality of the product, but also poses serious health risks to consumers. Therefore, it is of great importance to strictly comply with hygiene rules in the production of cosmetic products, to use appropriate preservatives and to regularly subject the products to microbiological tests. In addition, consumers should store and use the products correctly, which helps to reduce the risk of contamination (Yazici et al., 2023).

7. Microbiological Analysis Methods

7.1. Sampling and Preparation

The accuracy and reliability of microbiological analyses depend on correct sampling and preparation techniques. Sampling varies depending on the type of product to be analyzed, its packaging, and the purpose of the analysis. Taking samples under sterile conditions is critical to preventing contamination. Different sampling apparatus and techniques are used for solid products and liquid products. Preserving the integrity of the packaging, ensuring that the sample is representative, and taking a sufficient amount of sample are also important issues to consider. The sample preparation stage involves making the sample suitable for analysis. At this stage, processes such as dilution, neutralization, and homogenization can be applied. Dilution is performed to facilitate the analysis of samples with high microorganism density. Neutralization is used to eliminate the effect of antimicrobial substances in the product. Homogenization is applied to ensure that microorganisms are evenly distributed throughout the sample. It is important to maintain sterile conditions and avoid contamination during these processes (Gaitan Herrera, n.d.; Skowron et al., 2017).

7.2. Culture Methods

Culture methods, which are an indispensable part of microbiological analyses in cosmetic products, are a traditional approach that has proven its reliability and effectiveness for many years. These methods are widely used to determine the microorganism load in cosmetic products, to evaluate the microbiological quality of the product and especially to detect the presence of potential pathogens. The basic principle of culture methods is based on the incubation of samples taken from the product sample in a suitable medium at certain temperatures and times, and then counting and identifying the colonies that form. This approach focuses on the ability to detect and multiply the viability of microorganisms, providing comprehensive information about the microbial content of the product (Nemati et al., 2016; Zamorska et al., 2023).

7.3. Basic Principles And Application Of Culture Methods

Culture methods begin with the selection of a suitable growth medium. Nutrients, vitamins, minerals and other growth factors necessary for the growth of microorganisms are included in the growth medium

Commonly used culture media in cosmetic microbiology include:

- Plate Count Agar (PCA): Used for general aerobic bacterial counts.
- Sabouraud Dextrose Agar (SDA): Used for counting yeasts and molds.
- Tryptic Soy Agar (TSA): A general-purpose medium that promotes widespread growth of different types of microbes.

Sample inoculation should be done aseptically and can be performed by different methods.

- Surface seeding: It refers to spreading liquid samples (or diluted samples) on the surface of the growth medium.
- Pour seeding method: It refers to mixing the sample into melted and cooled growth medium, pouring it into a Petri dish and allowing it to solidify.

In samples with high microbial density, dilution processes are necessary to count colonies.

- Dilution: Usually done exponentially using sterile distilled water or buffer solutions (e.g. 1:10, 1:100, 1:1000).

Incubation is the process of keeping inoculated Petri dishes at optimum temperature and time. During the growth process, incubation temperature and

time should allow the target microorganisms to grow under optimum conditions.

- For bacteria: Routinely at 30-35°C for 24-48 hours
- For yeast and molds: 25-30°C for 3-5 days.

After the incubation period, the Petri dishes are counted and the number of colonies is multiplied by the dilution factor to obtain the microbial density (CFU/mL or CFU/g) (Bonnet et al., 2020; Halla et al., 2018; Kusumo et al., 2022; Nurfarahin et al., 2018).

7.4. Importance Of Selective and Differential Media

An introduction to selective and differential media is a fundamental aspect of culture methods. Selective media are media that support the growth of certain types of microorganisms while inhibiting the growth of other microorganisms. This facilitates the detection of target microorganisms. Differential media mean that different species can grow to form different colonies. An example of this is Mannitol Salt Agar (MSA), a selective and differential medium that detects *S. aureus*. Due to its high salt concentration, MSA inhibits the growth of other bacteria, while *S. aureus* ferments mannitol, causing a change in the color of the medium (Bonnet et al., 2020).

7.5. Advantages and Disadvantages Of Culture Methods

Cultural methods offer several advantages in the field of cosmetic microbiology. Firstly, these methods are highly effective in detecting and identifying viable microorganisms. Additionally, culture methods are relatively low-cost and can be conducted using basic laboratory equipment. However, there are also some disadvantages to consider. One significant drawback is that these methods can take a considerable amount of time to yield results, typically ranging from 24 hours to 5 days. Moreover, certain microorganisms may require specific conditions to grow, and not all microorganisms can be cultured successfully in a laboratory setting (Yapar et al., 2018).

7.6. The Role Of Culture Methods in Cosmetic Microbiology

Culture methods are essential for assessing the microbiological safety of cosmetic products. Common analyses performed using these methods include the total aerobic bacterial count (TAMC), total yeast and mold count (TYMC), and the detection of specific pathogens. These analyses help determine whether the microbial load of cosmetic products meets legal regulations and evaluate the effectiveness of preservative systems. Additionally, culture methods are

valuable for identifying sources of contamination in production processes and for monitoring the success of hygiene practices (Yapar et al., 2018).

7.8. Rapid Microbiological Methods

Rapid microbiological methods are methods that provide faster results and require less labor than traditional culture methods. These methods are usually automatic and highly effective.

7.8.1. Adenosine Triphosphate (ATP) Measurement

This method is based on measuring the amount of ATP found in all living biological cells. The amount of living microorganisms in the sample is represented by the amount of ATP. This smartphone-based technique provides a rapid assessment of general microbiological examination.

7.8.2. Impedance/conductivity measurement

It is based on detecting the metabolic activities and numbers of microorganisms by changes in the electrical properties of the growing substrate. It is usually applied in the microbiological examination of liquid products.

7.8.3. Flow cytometry

Using this method, individual cells are counted by measuring their optical/fluorescent properties. It provides rapid and accurate microorganism analysis.

7.8.4. Molecular methods (PCR, real-time PCR)

This method is based on the detection and amplification of nucleic acids (DNA and RNA). DNA amplification by PCR (Polymerase Chain Reaction) allows the identification of target microorganisms. This method is found in real-time PCR (qPCR), which monitors the DNA amplification reaction in progress and allows the quantification of microorganisms. Although high sensitivity and specificity can be achieved with molecular methods, these methods are increasingly used for rapid detection of pathogens (Bonnet et al., 2020).

8. Advantages and Disadvantages Of Rapid Microbiological Methods

Rapid microbiological methods offer many advantages over traditional culture methods, but they also have some disadvantages. Their advantages include providing faster results than traditional methods, requiring less labor, being suitable for automation, and offering high sensitivity and specificity, especially in molecular methods. However, these methods also have

disadvantages such as high initial cost (device and equipment), need for expert personnel, some methods not being able to detect all types of microorganisms, and some methods being affected by inhibitory substances. Therefore, the selection and application of rapid microbiological methods should be carefully evaluated according to the purpose of analysis, product type, and budget (Halla et al., 2018; Shintani, 2016).

9. Interpretation and Evaluation of Analysis Results

Interpretation and evaluation of results are critical in terms of verifying the safety and quality of the product and defining whether the microbial load of the product is within the specified limits, according to the acceptability criteria specified in legal regulations and relevant guidelines. The reliability and significance of the results are evaluated by statistical analysis of the obtained data; care should be taken not to ignore the potential causes of false positive or false negative results. The presence of non-compliant results that do not meet the specified acceptability criteria should be reported in detail so that source pollution is detected and harm to consumer health is minimized. While the quality of processed products is guaranteed, follow-up actions are implemented, including corrective measures (Alshehrei, 2024).

10. Quality Control and Assurance

Some of the most important elements contributing to the microbiological safety of many products, especially cosmetics, are quality control and assurance. It starts with the meticulous application of Good Manufacturing Practice (GMP) principles and is designed to limit the risk of contamination by maintaining a hygienic environment at every step of the production cycle. Data up to October 2023 has been used for assessments and HACCP (Hazard Analysis and Critical Control Points) risk assessment practices, enabling managers to effectively manage microbial risk. In addition, producer training, high hygiene standards, cleaning and disinfection of the production environment, monitoring of the water system, and detailed analysis of raw materials and packaging materials are important elements in quality control processes. For microbiological stability, it is essential to evaluate and optimize preservation systems (the potential to prevent microbial growth in the product formulation) throughout the shelf life (Almukainzi et al., 2022; Halla et al., 2018).

11. Preservative Systems and Efficacy Tests

Preservative systems play a critical role in protecting cosmetic products and similar formulations against microbial contamination and ensuring safety

throughout the consumer lifecycle; these systems ensure product stability and safety by inhibiting or killing the growth of microorganisms through preservatives such as parabens, formaldehyde-releasing agents, and phenoxyethanol. Optimization of preservative selection and concentration should be carefully done according to the product's characteristics and microbial risks to which it may be exposed, and preservative efficacy tests (challenge tests) should be applied to objectively assess how effective the product formulation is against microbial growth, particularly by the ISO 11930 standard. In recent years, innovative and more environmentally friendly preservative systems such as natural preservatives and antimicrobial peptides have been developed as alternatives to traditional preservatives and their potential use is being investigated (Halla et al., 2018; Murphy et al., 2021).

12. Regulations and Standards

The microbial safety of cosmetics and other consumer products is well-regulated by laws and international standards, with the European Cosmetics Regulation (EC No 1223/2009). This regulation defines substances prohibited for use in cosmetic products and the acceptance criteria for the microbial load of products. The FDA (Food and Drug Administration) provides comparable data for products on the US market. The ISO 22716 standard aims to reduce risks affecting the integrity, quality, and safety of cosmetic products through the application of Good Manufacturing Practice (GMP) principles in manufacturing processes, while the ISO 11930 standard provides standardized procedures to evaluate the effectiveness of antimicrobial preservation used in cosmetics to maintain microbial stability throughout the shelf life of the product. Regular updates to these regulations and standards are designed to promote public safety by providing information about the products we consume and to be used in conjunction with other national and international guidelines related to consumer health and Safety (Ferreira et al., 2022; Halla et al., 2018).

Conclusion

Sources of microbial contamination in cosmetic products can occur through raw materials, the production process, or packaging during and after production. Each can introduce different types and amounts of microorganisms to contaminate the product. Consequently, both cosmetic manufacturers and consumers should take precautions to reduce the risk of microbial contamination.

REFERENCES

Almukainzi, M., Alotaibi, L., Abdulwahab, A., Albukhary, N., & El Mahdy, A. M. (2022). Quality and safety investigation of commonly used topical cosmetic preparations. *Scientific Reports*, 12(1). doi: 10.1038/s41598-022-21771-7

Alnuqaydan, A. M. (2024). The dark side of beauty: an in-depth analysis of the health hazards and toxicological impact of synthetic cosmetics and personal care products. In *Frontiers in public health* (Vol. 12, p. 1439027). doi: 10.3389/fpubh.2024.1439027

Alshehrei, F. M. (2024). Microbiological Quality Assessment of Skin and Body care Cosmetics by using Challenge test. *Saudi Journal of Biological Sciences*, 31(4). doi: 10.1016/j.sjbs.2024.103965

Aras, A., & Eryilmaz, M. (2022). MICROBIOLOGICAL CONTAMINATION OF COSMETIC PRODUCTS. In Ankara Universitesi Eczacilik Fakultesi Dergisi (Vol. 46, Issue 1, pp. 262–276). University of Ankara. doi: 10.33483/jfpau.1027507

Bolouri, P., Salami, R., Kouhi, S., Kordi, M., Asgari Lajayer, B., Hadian, J., & Astatkie, T. (2022). Applications of Essential Oils and Plant Extracts in Different Industries. In *Molecules* (Vol. 27, Issue 24). MDPI. doi: 10.3390/molecules27248999

Bonnet, M., Lagier, J. C., Raoult, D., & Khelaifia, S. (2020). Bacterial culture through selective and non-selective conditions: the evolution of culture media in clinical microbiology. In *New Microbes and New Infections* (Vol. 34). Elsevier Ltd. doi: 10.1016/j_nmni.2019.100622

Bradley, C. G., & Corsini, L. (2023). A literature review and analytical framework of the sustainability of reusable packaging. In *Sustainable Production and Consumption* (Vol. 37, pp. 126–141). Elsevier B.V. doi: 10.1016/j.spc.2023.02.009

Brown, K. L., & Wray, S. (2013). Control of airborne contamination in food processing. In *Hygiene in Food Processing: Principles and Practice*: Second Edition (pp. 174–202). Elsevier Inc. doi: 10.1533/9780857098634.2.174

Catovic, C., Martin, S., Desaint, S., Borges, C., Lesouhaitier, H., Roullet, F., Bresciani, N., Jouault, A. M., Poulet, V., Luc, J., Joulia, V., Jupin, A., Masson, C., Crozier, A., & Feuilloley, M. G. J. (2020). Development of a standardized method to evaluate the protective efficiency of cosmetic packaging against microbial contamination. *AMB Express*, 10(1). doi: 10.1186/s13568-020-01016-4

Cristiano, L., & Guagni, M. (2022). Zooceuticals and Cosmetic Ingredients Derived from Animals. In Cosmetics (Vol. 9, Issue 1). MDPI. doi: 10.3390/cosmetics9010013

Dao, H., Lakhani, P., Police, A., Kallakunta, V., Ajjarapu, S. S., Wu, K. W., Ponkshe, P., Repka, M. A., & Narasimha Murthy, S. (2018). Microbial Stability of Pharmaceutical and Cosmetic Products. In AAPS PharmSciTech (Vol. 19, Issue 1, pp. 60–78). Springer New York LLC. doi: 10.1208/s12249-017-0875-1

Ferreira, M., Matos, A., Couras, A., Marto, J., & Ribeiro, H. (2022). Overview of Cosmetic Regulatory Frameworks around the World. In Cosmetics (Vol. 9, Issue 4). MDPI. doi: 10.3390/cosmetics9040072

Fouad, F. A., Youssef, D. G., Shahat, F. M., & Abd El-Ghany, M. N. (2023). Role of Microorganisms in Biodegradation of Pollutants. In Handbook of Biodegradable Materials (pp. 221–260). Springer International Publishing. doi: 10.1007/978-3-031-09710-2_11

Gaitan Herrera, A. (n.d.). Microbiological Cosmetics Analysis 293 293 Microbiological Analysis of Cosmetics. In Methods Mol Biol.

Ghias, M., & Fozouni, L. (2024). Assessment of Microbial Contamination and Metabolite Expo-sure in Cosmetic Products Used in Women's Beauty Salons. In Iran J Public Health (Vol. 53, Issue 5). Retrieved from <https://creativecommons.org/licenses/by-nc/4.0/>

Gupta, P. L., Rajput, M., Oza, T., Trivedi, U., & Sanghvi, G. (2019). Eminence of Microbial Products in Cosmetic Industry. In Natural Products and Bioprospecting (Vol. 9, Issue 4, pp. 267–278). Springer. doi: 10.1007/s13659-019-0215-0

Halla, N., Fernandes, I. P., Heleno, S. A., Costa, P., Boucherit-Otmani, Z., Boucherit, K., Rodrigues, A. E., Ferreira, I. C. F. R., & Barreiro, M. F. (2018). Cosmetics preservation: A review on present strategies. In Molecules (Vol. 23, Issue 7). MDPI AG. doi: 10.3390/molecules23071571

Ibrahim, B., & Kurt, A. A. (2024). Mikrobiyolojik Olarak Test Edilmiş Bitkisel Ekstraktlar ve Esansiyel Yağlar ile Saç Dökülmesine Karşı Doğal Şampuan Formülasyon Geliştirilmesi. *Journal of Immunology and Clinical Microbiology*, 9(1), 12-23.

Ibrahim, I. D., Hamam, Y., Sadiku, E. R., Ndambuki, J. M., Kupolati, W. K., Jamiru, T., Eze, A. A., & Snyman, J. (2022). Need for Sustainable Packaging: An Overview. In Polymers (Vol. 14, Issue 20). MDPI. doi: 10.3390/polym14204430

Kim, H. W., Seok, Y. S., Cho, T. J., & Rhee, M. S. (2020). Risk factors influencing contamination of customized cosmetics made on-the-spot: Evidence from the national pilot project for public health. *Scientific Reports*, 10(1). doi: 10.1038/s41598-020-57978-9

Kurt, A. A., & Ibrahim, B. (2024). Development and Microbiological Evaluation of Natural Diaper Rash (Diaper Dermatitis) Cream Formulations. *Journal of Immunology and Clinical Microbiology*, 9(1), 1-11.

Kurt, A. A., & Ibrahim, B. (2024). New generation natural face cream formulation: development and in vitro evaluation. *Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi*, 11(4), 672-680.

Kusumo, Y., Atmanto, A. A., Handayani, I., & Paramita, K. (2022). CULTURE MEDIA. Article in *International Journal of Current Research in Science Engineering & Technology*. Retrieved from www.irjmets.com

Lundov, M. D., Moesby, L., Zachariae, C., & Johansen, J. D. (2009). Contamination versus preservation of cosmetics: A review on legislation, usage, infections, and contact allergy. In *Contact Dermatitis* (Vol. 60, Issue 2, pp. 70–78). doi: 10.1111/j.1600-0536.2008.01501.x

Murphy, B., Hoptroff, M., Arnold, D., Eccles, R., & Campbell-Lee, S. (2021). In-vivo impact of common cosmetic preservative systems in full formulation on the skin microbiome. *PLoS ONE*, 16(7 July). doi: 10.1371/journal.pone.0254172

Nemati, M., Hamidi, A., Dizaj, S. M., Javaherzadeh, V., & Lotfipour, F. (2016). An overview on novel microbial determination methods in pharmaceutical and food quality control. In *Advanced Pharmaceutical Bulletin* (Vol. 6, Issue 3, pp. 301–308). Tabriz University of Medical Sciences. doi: 10.15171/apb.2016.042

Nurfarahin, A. H., Mohamed, M. S., & Phang, L. Y. (2018). Culture medium development for microbial-derived surfactants production—an overview. In *Molecules* (Vol. 23, Issue 5). MDPI AG. doi: 10.3390/molecules23051049

Patel, R., Vhora, A., Jain, D., Patel, R., Khunt, D., Patel, R., Dyawanapelly, S., & Junnuthula, V. (2024). A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023. In *Drug Discovery Today* (Vol. 29, Issue 6). Elsevier Ltd. doi: 10.1016/j.drudis.2024.103993

Poddębniak, P., & Kalinowska-Lis, U. (2024). A Survey of Preservatives Used in Cosmetic Products. *Applied Sciences (Switzerland)*, 14(4). doi: 10.3390/app14041581

Rocca, R., Acerbi, F., Fumagalli, L., & Taisch, M. (2022). Sustainability paradigm in the cosmetics industry: State of the art. *Cleaner Waste Systems*, 3. doi: 10.1016/j.clwas.2022.100057

Sarruf, F. D., Contreras, V. J. P., Martinez, R. M., Velasco, M. V. R., & Baby, A. R. (2024). The Scenario of Clays and Clay Minerals Use in Cosmetics/Dermocosmetics. In Cosmetics (Vol. 11, Issue 1). Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/cosmetics11010007

Sawicka, B., & Noaema, A. H. (2016). Safety of plant cosmetic raw materials. *International Journal of Research & Methodology in Social Science*. Retrieved from www.socialsciencepublication.com

Shintani, H. (2016). Methods of rapid microbiological assay and their application to pharmaceutical and medical device fabrication. In Bioccontrol Science (Vol. 21, Issue 4, pp. 193–201). Society for Antibacterial and Antifungal Agents Japan. doi: 10.4265/bio.21.193

Skowron, K., Budzyńska, A., Kaczmarek, A., & Grudlewska, K. (2017). Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date. *Roczniki Państwowego Zakładu Higieny*. Retrieved from <https://www.researchgate.net/publication/317903586>

Yadav, G. V., Khunger, S., & Kunal. (2023). Allergic Contact Dermatitis Due to Chemical Agents and Microbial Contamination in Cosmetic Products: A Review. In Journal of Pure and Applied Microbiology (Vol. 17, Issue 3, pp. 1391–1399). Journal of Pure and Applied Microbiology. doi: 10.22207/JPAM.17.3.04

Yapar, E. A., & Cengiz, G. (2018). International Standards of Microbiological Quality in Cosmetic Products. In Curr. Pers. MAPs (Vol. 2).

Yazici, E. K., & Eryilmaz, M. (2023). INVESTIGATION OF THE MICROBIOLOGICAL CONTAMINATION OF USED LIPSTICKS AND MASCARAS. *Ankara Universitesi Eczacilik Fakultesi Dergisi*, 47(1), 269–276. doi: 10.33483/jfpau.1209451

Zamorska, J., Karwowska, E., & Przystaś, W. (2023). Assessment of Microbiological Quality of Water Using Culture Methods, Flow Cytometry and Luminometry. *Water (Switzerland)*, 15(23). doi: 10.3390/w15234077

Chapter 2

Microbiological Analysis and Methods in Medicine and Cosmetics

Bashar IBRAHIM¹

İsmail ASLAN²

Abstract

The evolving regulatory landscape and rising risks are particularly significant in the pharmaceutical industry. This sector faces ongoing pressure to adhere to Good Manufacturing Practices (GMP) and microbiological control standards, both of which are critical for the safe and effective production of medicines. GMP encompasses various controls, including measures to prevent microbial contamination, establish limits, conduct monitoring, ensure sterilization, and maintain thorough documentation. Risks associated with raw materials, environmental factors, personnel, and water systems are managed through strategies such as cleaning, sterilization, filtration, and the use of up-to-date testing methods. Growing regulatory pressures, along with the emergence of products like biologics and antibiotic-resistant strains, compel manufacturers to continuously optimize and innovate, thereby enhancing the safety and quality of products intended for patients. This study aims to address the importance of microbiological analyses and methods used in the pharmaceutical and cosmetic sectors, especially within the framework of GMP and microbiological control standards.

Keywords: Good Manufacturing Practices, Pharmaceutical and Cosmetic Industry, Microbial Contamination, Product Safety, Quality Control

¹ Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Süleyman Demirel University, Isparta 23000 Turkiye. basharibrahim@sdu.edu.tr ORCID No: 0000-0003-3086-0995

² University of Health Sciences Türkiye, Hamidiye Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Türkiye ; ismail.aslan@sbu.edu.tr, 0000-0001-7075-7103

Introduction

Since the safety and effectiveness of pharmaceutical and cosmetic products are directly related to human health, microbiological analyses are of vital importance in these industries. A range of cosmetic products, including face creams, masks, herbal toothpastes, herbal shampoos and baby rash creams, should be subjected to microbiological testing (Kurt et al., 2024). A similar approach should be adopted with pharmaceutical products, such as tablets and topical gels (Aslan et al., 2024, Kurt et al., 2024). Microbiological analyses are carried out regularly at every stage of the production processes, starting from the acceptance of raw materials, during packaging and storage conditions, and before the final products are released to the market. The main purpose of these analyses is to ensure that the products are safe in terms of microbial contamination and to protect consumer health. Microorganisms that may be present in pharmaceutical and cosmetic products can disrupt the structure of the product, reduce its effectiveness, and even harm human health by producing toxic metabolites. Therefore, microbiological analyses are used not only to detect the presence of pathogenic microorganisms, but also to determine the general microbial load of products, to assess the hygienic conditions of production processes, and to verify the effectiveness of appropriate preservative systems. The scope of microbiological analyses may vary depending on the type of product, its intended use, production methods, and relevant legal regulations (Haleem et al., 2015; Sultana et al., 2015).

The methods used for microbiological analysis of pharmaceutical and cosmetic products cover a wide range from traditional culture techniques to modern molecular biology methods. Traditional culture methods are based on the principle of growing microorganisms in suitable culture media and counting their colonies. These methods are widely used to determine general microbial load, especially total aerobic bacteria count, mold and yeast count. In addition, selective culture media and biochemical tests are used for the detection and identification of certain pathogenic microorganisms (e.g. *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Candida albicans*) (Akgül et al., 2021; Bonnet et al., 2020; Zhang et al., 2021, Kurt, 2014). Rapid test kits are an alternative method that works based on antibody-antigen interaction and provides results in a shorter time. These kits are ideal for rapid microbial screening, especially in production processes. Molecular biology techniques (e.g. PCR, real-time PCR) provide rapid and specific identification of microorganisms through amplification and detection of DNA or RNA. These methods are particularly valuable for the detection of microorganisms that are difficult to identify or cannot be grown in culture. The selection of

microbiological analysis methods should be carefully made according to the purpose of the analysis, the characteristics of the product, the possibilities of the laboratory, and legal requirements (Zhang et al., 2021, Kurt et al., 2024, Ibrahim et al., 2024). Yüz kremleri, maskeler, bitkisel dış macunları, bitkisel sampuanlar ve bebek pişik kremleri mikrobiyolojik olarak test edilemsi gereken bazı kozmetik ürünlerdir (Kurt et al., 2024).

In the pharmaceutical and cosmetic industries, microbiological analyses should extend beyond just testing products; they must be integral to a comprehensive microbial control and quality assurance system. These systems encompass a series of preventive measures, which include selecting raw materials, designing production processes, ensuring personnel hygiene, and conducting the cleaning and disinfection of equipment. Additionally, monitoring packaging and storage conditions is essential. Microbial control programs should be bolstered by regular environmental monitoring, including air sampling and surface swabs, as well as water analyses. These assessments are crucial for identifying potential sources of contamination and implementing necessary corrective actions. Furthermore, quality assurance systems must incorporate validation studies, the use of reference standards, and regular inspections to ensure the accuracy and reliability of microbiological analyses (Halla et al., 2018; Roesti et al., 2019).

To ensure product safety and protect consumer health, pharmaceutical and cosmetic manufacturers must establish and implement comprehensive microbial control and quality assurance systems. These systems should align with Good Manufacturing Practice (GMP) principles and relevant national and international standards, such as ISO 22716. By doing so, manufacturers can systematically monitor the microbial quality of their products, minimize risks, and continuously confirm that their products meet established standards (Venkatesh D, 2023). The aim of the study is to ensure the safety of pharmaceutical and cosmetic products through microbiological analysis and GMP; to comply with regulatory changes and to develop solutions against new risks.

GMP and Basic Principles Of Microbiological Control

GMP, is a set of regulations and guidelines implemented in the pharmaceutical industry to ensure product quality and safety. The main purpose of GMP is to ensure that medicines are manufactured safely, effectively, and as intended (Gouveia et al., 2015). To achieve its goals, Good Manufacturing Practices (GMP) require strict quality control measures at every stage of the manufacturing process. This includes everything from procuring raw materials

to releasing the final product into the market. Microbiological control is a crucial aspect of GMP and encompasses a set of strategies and procedures aimed at preventing and managing microbial contamination in pharmaceutical products. Therefore, it is essential for professionals in the pharmaceutical industry to understand the fundamental principles of microbiological control (Swarbrick J, 2005).

1. Preventing Contamination: A Proactive Approach

Preventing microbial contamination is one of the most fundamental principles of GMP regarding microbiological control. This principle requires taking proactive measures to prevent contamination from occurring. Factors such as the design of production facilities, equipment selection, and personnel hygiene should be optimized to minimize microbial contamination (Mohammad ZH, 2024).

- Facility Design: Production areas should be easily cleaned, disinfected, and ventilated. Airflow should be from clean areas to less clean areas, and appropriate ventilation systems (such as HEPA filters) should be used to control the number of particles and microorganisms in the air. The facility design should also provide adequate physical separation between different production stages.
- Equipment Selection: Production equipment should be made of materials that can be easily cleaned, disinfected, and sterilized. The equipment design should prevent dead spots and hard-to-clean areas. In addition, equipment should be regularly maintained and calibrated.
- Personnel Hygiene: Production personnel must adhere to strict hygiene protocols. These protocols include regular hand washing, wearing appropriate clothing (such as cleanroom clothing), wearing masks and gloves, and not bringing food, beverages, or personal items into production areas. It is important that personnel are regularly trained on hygiene protocols and that the effectiveness of the practices is monitored (Chawla et al., 2023; Gilleskie et al., n.d.; Mohammad ZH, 2024).

2. Determination of Microbial Limits: Acceptable Risk Levels

Determination of acceptable microbial limits for raw materials, intermediate products, and final products is another important principle of GMP. These limits are determined by considering factors such as the intended use of the product, the risk to the patient, and the nature of the product. If microbial limits are exceeded, the safety and effectiveness of the product may be compromised.

Therefore, necessary corrective and preventive actions (CAPA) should be implemented in case of exceedance of the limits (Ghias et al., 2024).

- Raw Materials: Microbial limits for raw materials should be controlled through supplier qualification, raw material testing, and acceptance criteria. Higher risk raw materials should have stricter limits and more extensive testing.
- Intermediate Products: Intermediate products in the manufacturing process should be tested regularly to prevent the spread of microbial contamination. Microbial limits for intermediate products should be determined by considering the ability of subsequent manufacturing stages to reduce microbial load.
- Final Products: Microbial limits for final products should be in accordance with standards established by pharmacopoeia (e.g. USP, EP) or other regulatory authorities. For sterile products, the microbial limit is a sterility test and requires the product to be sterile. For non-sterile products, limits are established for specific types of microorganisms such as total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) (Ghias et al., 2024; Myemba et al., 2022; Ratajczak et al., 2015).

3. Microbial Monitoring and Testing: Continuous Surveillance and Early Warning

The production environment, water systems, personnel, and products should be subjected to regular microbial monitoring and testing. This allows potential sources of contamination to be identified and necessary precautions to be taken. Microbial monitoring and testing are critical to verify that the production process is under control and that microbial limits are not exceeded.

- Environmental Monitoring: Air, surfaces and equipment in production areas should be regularly monitored for microbial contamination. Air samples can be taken using active or passive methods. Surface samples can be taken using swabs or contact plates. The data obtained should be used for trend analysis and the causes of deviations should be investigated.
- Water System Monitoring: Water systems used in pharmaceutical production should be regularly monitored for microbial contamination. Water samples should be taken at regular intervals and tested for total coliform, *Pseudomonas aeruginosa* and other relevant microorganisms.
- Personnel Monitoring: The hands and clothing of production personnel should be regularly monitored for microbial contamination. This is important to verify that personnel are adhering to hygiene protocols and to identify potential sources of contamination.

Product Testing: Raw materials, intermediates, and finished products should be tested for microbial contamination. Test results should be used to verify compliance with microbial limits and ensure product Safety (Ghias et al., 2024; Halla et al., 2018).

4. Sterilization and Disinfection: Strategies for the Elimination and Inactivation of Microorganisms

In the production of sterile pharmaceutical products, the implementation of validated sterilization techniques—such as autoclaving and dry heat sterilization—is imperative. Sterilization is defined as the complete eradication of all viable microorganisms, including bacteria, fungi, viruses, and spores. The selection of an appropriate sterilization method must be based on the physicochemical characteristics of the product components and their packaging materials to ensure efficacy and product integrity. In addition to sterilization, routine disinfection of manufacturing environments and equipment is essential to mitigate the risk of microbial contamination. Disinfection, in contrast to sterilization, refers to the reduction of microbial populations to levels considered acceptable according to regulatory standards.

- ***Sterilization Methods:***

- Autoclave: Autoclave is a method that provides sterilization using pressurized steam. It is generally used for the sterilization of heat-resistant materials (glass, metal) and some liquids.
- Dry Heat: Dry heat is a method that provides sterilization at high temperatures (usually 160-180°C). It is used for the sterilization of heat-resistant, moisture-free materials (glassware, metal tools).
- Filtration: Filtration is the process of removing microorganisms by passing them through filters smaller than their pore size. It is widely used for the sterilization of heat-sensitive liquids.
- Irradiation: Irradiation is a method that provides sterilization using gamma rays or electron beams. It is used for the sterilization of single-use medical devices and some drugs (Küng Biotech et al., 2016; McDonnell, n.d.).

- ***Disinfection Methods:***

- Chemical Disinfectants: Chemical disinfectants (alcohol, chlorine compounds, quaternary ammonium compounds, etc.) are used to reduce the number of microorganisms on surfaces. The effectiveness of disinfectants is affected by factors such as contact time, concentration,

and the presence of organic matter (Mangkoedihardjo et al., 2023; Meade et al., 2018).

- UV Light: UV light is a method that inactivates microorganisms in the air and on surfaces by damaging their DNA. UV light is especially effective in air disinfection (Mangkoedihardjo et al., 2023; Meade et al., 2018).

5. Validation and Qualification: Proving Continuous Performance

All critical processes (sterilization, disinfection, filtration, etc.) must be validated and equipment must be qualified. Validation is a documented process to prove that a process or system will consistently produce the intended results. Qualification is a documented process to prove that equipment meets specified requirements and performs as intended.

- Validation: Validation of critical processes such as sterilization, disinfection, and filtration is necessary to verify the efficiency and reliability of the process. Validation protocols should determine process parameters (temperature, pressure, time, filter size, etc.) and define acceptable limits (Jairoun et al., 2022; Nguyen, 2020; Vincent, 2015).
- Qualification: Qualification of production equipment is necessary to verify that the equipment is installed correctly (IQ), performs as expected (OQ), and performs consistently (PQ). Qualification protocols should evaluate all critical parameters that have an impact on the performance of the equipment (temperature, pressure, speed, etc.) (Jairoun et al., 2022; Nguyen, 2020; Vincent, 2015).

6. Documentation: Traceability and Accountability

All microbiological control activities should be documented in detail. This documentation is an important reference source during audits and problem-solving processes. Documentation should include records of all microbiological control procedures, test results, deviations, corrective and preventive actions (CAPA), and validation/qualification reports.

- Procedures: All procedures related to microbiological control (e.g., environmental monitoring, water system monitoring, sterilization, disinfection, test methods) should be documented in writing and understood by personnel (Confessor Castilho Lopes et al., 2022; Siegert, 2010; Vincent, 2015).
- Test Results: All microbiological test results should be recorded in detail, including test date, sample location, test method, results, and comments.

- Deviations: All deviations, such as exceeding microbial limits or other unexpected results, should be investigated and recorded in detail. The causes of deviations should be determined and appropriate corrective and preventive actions (CAPA) should be implemented.
- CAPA: Corrective and preventive actions (CAPA) are measures that should be taken to correct deviations and prevent recurrence. CAPAs may vary depending on the cause of the deviation and generally include activities such as revision of procedures, training of personnel, maintenance of equipment, or changes in facility design.
- Validation/Qualification Reports: The results of validation and qualification studies should be documented in detailed reports. Reports should include protocols used, test results, deviations and conclusions (Confessor Castilho Lopes et al., 2022; Siegert, 2010; Vincent, 2015).

Conclusion

The basic principles of GMP and microbiological control are vital to ensure the quality and safety of pharmaceutical products. Contamination prevention, microbial limit determination, microbial monitoring and testing, sterilization and disinfection, validation and qualification, and documentation are the fundamental elements required to manage and control microbial risks in pharmaceutical manufacturing. Strict adherence to these principles is essential to ensure patient safety and protect the reputation of the pharmaceutical industry. Professionals in the pharmaceutical industry must understand and apply the basic principles of GMP and microbiological control to create a culture focused on continuous improvement and patient safety.

References

Akgül, Ö., & Bakan, K. (2021). The aerobic bacteria isolated from used cosmetic products and evaluation of antibiotic resistance. Ankara Universitesi Eczacilik Fakultesi Dergisi, 45(2), 156–168. doi: 10.33483/jfpau.850561

Bonnet, M., Lagier, J. C., Raoult, D., & Khelaifia, S. (2020). Bacterial culture through selective and non-selective conditions: the evolution of culture media in clinical microbiology. In *New Microbes and New Infections* (Vol. 34). Elsevier Ltd. doi: 10.1016/j.nmni.2019.100622

Chawla, H., Anand, P., Garg, K., Bhagat, N., Varmani, S. G., Bansal, T., McBain, A. J., & Marwah, R. G. (2023). A comprehensive review of microbial contamination in the indoor environment: sources, sampling, health risks, and mitigation strategies. In *Frontiers in Public Health* (Vol. 11). Frontiers Media SA. doi: 10.3389/fpubh.2023.1285393

Confessor Castilho Lopes, C., Scheffmacher, F., Nardi, G., Barbosa Lopes, E., Castilho Lopes, L., dos Santos, D., Gamio Dias, T., Moraes da Costa, M., Sergio Silva, P., Vinicius Bealuka, L., Bottesini dos Santos, L., Moreira Souza, A., Ribeiro, M., Cavanus Fontana, I., Balbinoti Fuzinatto, S., Vitor Freitas Bertuci, J., Alves dos Anjos, G., Herget Pitanga, F., Basso Dala Costa, L., ... Lemos, M. (2022). MICROBIOLOGICAL CONTAMINATION IN COSMETICS. *International Journal of Development Research*. doi: 10.37118/ijdr.25348.09.2022

Ghias, M., & Fozouni, L. (2024). Assessment of Microbial Contamination and Metabolite Expo-sure in Cosmetic Products Used in Women's Beauty Salons. In *Iran J Public Health* (Vol. 53, Issue 5). Retrieved from <https://creativecommons.org/licenses/by-nc/4.0/>

Gilleskie, G. L., & Hentz, N. (n.d.). Biopharmaceutical microbial contamination control processes, equipment, facilities, and systems to prevent microbial contamination. *Pharmaceutical Processing*. Retrieved from <https://www.researchgate.net/publication/286390426>

Gouveia, B. G., Rijo, P., Gonçalo, T. S., & Reis, C. P. (2015). Good manufacturing practices for medicinal products for human use. In *Journal of Pharmacy and Bioallied Sciences* (Vol. 7, Issue 2, pp. 87–96). Wolters Kluwer Medknow Publications. doi: 10.4103/0975-7406.154424

Haleem, R. M., Salem, M. Y., Fatahalla, F. A., & Abdelfattah, L. E. (2015). Quality in the pharmaceutical industry - A literature review. In *Saudi Pharmaceutical Journal* (Vol. 23, Issue 5, pp. 463–469). Elsevier B.V. doi: 10.1016/j.jsps.2013.11.004

Halla, N., Fernandes, I. P., Heleno, S. A., Costa, P., Boucherit-Otmani, Z., Boucherit, K., Rodrigues, A. E., Ferreira, I. C. F. R., & Barreiro, M. F. (2018). Cosmetics preservation: A review on present strategies. In *Molecules* (Vol. 23, Issue 7). MDPI AG. doi: 10.3390/molecules23071571

Jairoun, A. A., Al-Hemyari, S. S., Shahwan, M., Jamshed, S., & Bisgwa, J. (2022). Development and validation of a novel cosmetics safety assessment scale (CSAS): Factual understanding of cosmetic safety and fostering international awareness. *PLoS ONE*, 17(11 November). doi: 10.1371/journal.pone.0276938

ASLAN, İ., & KURT, A. A. (2024). Evaluation of the physical properties of an orodispersible tablet containing melatonin and pyridoxine HCl (Vitamin B6). *Journal of Research in Pharmacy*, 28(6).

Ibrahim, B., & Kurt, A. A. (2024). Mikrobiyolojik Olarak Test Edilmiş Bitkisel Ekstraktlar ve Esansiyel Yağlar ile Saç Dökülmesine Karşı Doğal Şampuan Formülasyon Geliştirilmesi. *Journal of Immunology and Clinical Microbiology*, 9(1), 12-23.

Kurt, Ahmet Arif, Bebek pişik önleyici krem formülasyonu üzerine çalışmalar, İstanbul, Yeditepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Yüksek Lisans Tezi, 2014.

Kurt, A. A., & Ibrahim, B. (2024). Development and Microbiological Evaluation of Natural Diaper Rash (Diaper Dermatitis) Cream Formulations. *Journal of Immunology and Clinical Microbiology*, 9(1), 1-11.

Kurt, A. A., & Ibrahim, B. (2024). New generation natural face cream formulation: development and in vitro evaluation. *Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi*, 11(4), 672-680.

Kurt, A. A., & Aslan, İ. (2025). A Novel Liposomal In-Situ Hydrogel Formulation of Hypericum perforatum L.: In Vitro Characterization and In Vivo Wound Healing Studies. *Gels*, 11(3), 165.

Küng Biotech, I., Bagutti, C., Binz, T., Mazza, G., Stadler, C., Summermatter, K., & Biebinger, S. (2016). Chemical Inactivation of Organisms in Liquids Guidelines for the chemical inactivation of organisms in liquid cultures or supernatants with proof of efficacy and safe disposal Chemical Inactivation of Organisms in Liquids. Federal Office of Public Health.

Mangkoedihardjo, S., & Al-Rosyid, L. M. (2023). Chemical disinfectants detoxify wastewater containing various organic substances.

Environmental Research and Technology, 6(1), 8–12. doi: 10.35208/ert.1208362

Mcdonnell, G. (n.d.). Sterilization and Disinfection. *Applied Microbiology*.

Meade, E., & Garvey, M. (2018). Efficacy testing of novel chemical disinfectants on clinically relevant microbial pathogens. *American Journal of Infection Control*, 46(1), 44–49. doi: 10.1016/j.ajic.2017.07.001

Mohammad ZH, A. R. E. A. F. J. VK. (2024). Microbial Contamination in the Food Processing Environment. *Microbial Biotechnology in the Food Industry*.

Myemba, D. T., Bwire, G. M., & Sangeda, R. Z. (2022). Microbiological Quality of Selected Local and Imported Non-Sterile Pharmaceutical Products in Dar es Salaam, Tanzania. *Infection and Drug Resistance*, 15, 2021–2034. doi: 10.2147/IDR.S355331

Nguyen, T. T. N. (2020). Developing and validating five-construct model of customer satisfaction in beauty and cosmetic E-commerce. *Heliyon*, 6(9). doi: 10.1016/j.heliyon.2020.e04887

Ratajczak, M., Kubicka, M. M., Kamińska, D., Sawicka, P., & Długaszevska, J. (2015). Microbiological quality of non-sterile pharmaceutical products. *Saudi Pharmaceutical Journal*, 23(3), 303–307. doi: 10.1016/j.jsps.2014.11.015

Roesti, D., & Goverde, M. (2019). Pharmaceutical Microbiological Quality Assurance and Control: Practical Guide for Non-Sterile Manufacturing. In *Pharmaceutical Microbiological Quality Assurance and Control: Practical Guide for Non-Sterile Manufacturing*. wiley. doi: 10.1002/9781119356196

Sieger, W. (2010). Evaluation of the Microbiological Safety of Finished Cosmetic Products. Retrieved from www.schuelke.com

Sultana, A., Jamil Bhuiyan, S., Akhter Purni, F., Binte Bahar, N., Mostafa Ahmed, M., Rafat Tahsin, M., Haq, E., Khondoker, S., Jannat Koly, F., Afrin, S., Islam Tithi, T., Anjum, J., Rezwan, R., Ferdousy, S., Ahmed Chowdhury, J., Kabir, S., Asad Choudhury, A., Aktar, F., & Shah Amran, M. (2015). GOOD MANUFACTURING PRACTICE (GMP) GUIDELINE IN PHARMACEUTICAL INDUSTRIES: IMPLEMENTATION AND ITS SIGNIFICANCE FROM THE VIEW OF PHARMACISTS. In *International Journal of Modern Pharmaceutical Research* (Vol. 6). Retrieved from www.ijmpronline.com

Swarbrick J. (2005). Good Design Practices for GMP Pharmaceutical Facilities. Taylor & Francis Informa.

Venkatesh D, N. (2023). A Review on the Cosmetics Rule 2020 and ISO 22716. Biomedical Journal of Scientific & Technical Research, 53(5). doi: 10.26717/bjstr.2023.53.008469

Vincent, Ursula. (2015). JRC guidelines for selecting and. Guidelines for Cosmetic Products' Analysis, 20.

Zhang, S., Li, X., Wu, J., Coin, L., O'brien, J., Hai, F., & Jiang, G. (2021). Molecular methods for pathogenic bacteria detection and recent advances in wastewater analysis. In Water (Switzerland) (Vol. 13, Issue 24). MDPI. doi: 10.3390/w13243551

Chapter 3

Microbial Safety of Biopharmaceutical Products

Bashar IBRAHIM¹

Buse ZEREN²

Abstract

Biopharmaceutical products have become a vital component of modern medicine, significantly improving the management of various conditions, including cancer, autoimmune diseases, and infectious diseases. Since the manufacturing processes for these products involve living organisms or cells, there is a significant risk of microbial contamination. Inadequate control measures can lead to such contamination, jeopardizing product safety and efficacy, and potentially harming patient health. Therefore, all manufacturing steps must be designed to ensure and maintain the microbial safety of biopharmaceutical products. This review highlights the importance of microbial safety in the biopharmaceutical industry, identifies sources of microbial contamination, discusses principles of risk assessment, outlines microbial control strategies, and examines current regulatory requirements in this critical field.

Keywords: Biopharmaceutical Products, Microbial Safety, Microbial Contamination, Risk Assessment

¹ Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Süleyman Demirel University, Isparta 23000 Turkiye. basharibrahim@sdu.edu.tr ORCID No: 0000-0003-3086-0995

² bussezeren@gmail.com ORCID No: 0009-0002-7052-4769

Introduction

Drugs produced using advanced biological methods such as recombinant DNA technology, monoclonal antibody production, and cell culture are generally known as biopharmaceuticals and have become an integral part of modern medicine [Kesik et al., 2018)]. These products have more complex molecular structures than traditional chemical-based drugs, often consisting of larger molecules such as proteins, nucleic acids, and cell-based therapies. Because of this complexity, biopharmaceuticals tend to be more selective and effective in the biological processes they target, but their manufacturing processes are also often complex and delicate [Alhazmi et al., 2023]. Cell cultures and living organisms used in the production of biopharmaceuticals significantly increase the risk of microbial contamination. Products or production environments can be contaminated with bacteria, fungi, viruses, and other microorganisms. Microbial contamination not only affects product quality but can also cause toxic effects and even death in patients. Therefore, providing microbial assurance in the biopharmaceutical industry is extremely important to protect patient health and ensure product efficacy [Kuystermans et al., 2015, Javanmard et al., 2023]. Microbial contamination can lead to a range of problems, from product destabilization to loss of therapeutic efficacy to immunogenicity. Furthermore, when a contaminated product is withdrawn from the market, it can cause serious reputational damage and major financial losses for the manufacturer. Therefore, it is imperative to take comprehensive measures to prevent and control microbial contamination in biopharmaceutical manufacturing processes. These measures cover everything from selecting raw materials to validating the manufacturing process, training personnel, hygiene measures, and final product testing. Microbial safety is a requirement in the biopharmaceutical industry, and understanding its importance and seeking continuous improvements is critical to ensuring patient safety and the sustainability of the industry [Tang et al., 2024, Fajdek-Bieda et al., 2025]. This study aims to draw attention to the risk of microbial contamination in biopharmaceutical products and to emphasize the critical importance of microbial safety in terms of patient safety and product efficacy.

Risk Assessment and Control Strategies

Ensuring microbial safety of biopharmaceutical production relies on the development of a robust risk assessment and mitigation strategy [Pashang et al., 2024]. Risk assessment refers to the process of identifying potential sources of contamination that could impact product quality and patient safety. It involves a thorough evaluation of all possible risks throughout the entire manufacturing

process, which includes raw material procurement, cell culture, purification, formulation, filling, and packaging. There are several methods used for risk assessment, such as Hazard Analysis and Critical Control Points (HACCP) and Failure Modes and Effects Analysis (FMEA), along with other structured risk assessment tools. These techniques help determine appropriate control measures by evaluating factors such as likelihood, impact, and probability of detection [Ito et al., 2023]. The risk control strategy should involve a series of measures designed to reduce or eliminate identified risks. These measures can be categorized into three groups: preventive controls, detective controls, and corrective actions. Preventive controls focus on avoiding contamination and include practices such as good manufacturing practices (GMP), sterilization and disinfection procedures, air quality management, and personnel hygiene. Pharmaceutical and cosmetic products include dispersible tablets, nanocarrier systems, creams, masks, herbal products, which are specified in the regulations published by Titck in Turkey and the rules are followed in research (Kurt et al., 2024, Kurt et al., 2024, Aslan et al., 2024). The cell culture phase is particularly vulnerable to contamination because cells are grown in a nutrient-rich environment environment that supports microbial growth. Therefore, it is crucial to rigorously apply aseptic techniques, use only sterile equipment and consumables, and routinely inspect the cell culture medium [Glevitzky et al., 2025, Suvikas-Peltonen et al., 2017]. There is a risk of contamination during the protein and biomolecule separation purification stage. At this stage, cleaning and sterilization of chromatography columns and other equipment, removal of endotoxins and other pyrogens, and viral inactivation or removal steps are required [Schneier et al., 2020]. The final product test serves as a crucial checkpoint to verify the sterility and quality of a product. These tests adhere to the standards established by pharmacopeias, including the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), and the Japanese Pharmacopoeia (JP). However, because the final product test only examines a limited number of samples, it may not always be adequate for detecting contamination. Therefore, it is essential to implement a robust control strategy at every stage of the production process. The results of the final product tests should be analyzed alongside other relevant data. In the biopharmaceutical sector, the final product test is conducted according to the standards of pharmacopeias (USP, EP, JP) to ensure that the product is both safe and of high quality. These tests primarily include microbiological sterility tests, microbial limit tests, and endotoxin tests. Microbial limit tests are performed to identify and quantify specific microorganisms in a product. Endotoxin tests are specifically targeted to detect the presence of endotoxins, which are found in the cell walls of Gram-negative bacteria and can cause fever

in humans. However, a major obstacle with end-product testing is the low probability of detecting contamination, depending on the sampling plan used. By testing a limited number of samples, they may not be representative of the entire production batch and low-level contamination may not be detected. This means that end-product testing is not always sufficient to detect contamination, as only a few samples are tested, highlighting the vitality of strict controls at every stage of production [Jouette et al., 2017].

Microbial Control Methods

Sterilization

Product safety and efficacy in biopharmaceutical manufacturing begins with sterilization. This is done to properly destroy all life forms (e.g. bacteria, viruses, fungi, protists, and spores) present in a substance or medium. Microorganisms can be present in products, posing a risk of contamination, and compromising patient safety and the therapeutic efficacy of drugs. Therefore, the application of validated sterilization processes is essential in the production of biopharmaceutical products. There are a variety of sterilization methods suitable for specific biopharmaceutical products and manufacturing processes. These strategies focus on the essential cellular structures or metabolic pathways that are vital to the survival of microorganisms [Mohapatra et al., 2017].

The Most Commonly Used Methods

Steam Sterilization (Autoclave)

An autoclave is a device that sterilizes under saturated steam with high temperature and pressure. This steam penetrates the cell walls of microorganisms, causing protein denaturation and inactivation [Hossain et al., 2012].

Autoclave (steam sterilizer) is a common, efficient and reliable method for heat-resistant materials (e.g. glassware, metal instruments and some solutions). Parameters such as temperature, pressure and time are carefully monitored to ensure the effectiveness of sterilization [Montero et al., 2018].

Dry Heat Sterilization: This method uses dry heat under high temperatures (usually 160-180°C) to destroy microorganisms. Oxidation in dry heat damages cell components, causing cell death of microorganisms [Darmady et al., 1961].

Because dry heat sterilization is performed without moisture, it is compatible with heat-sensitive materials (such as glassware, metal instruments, and certain powdered materials) and can better tolerate potential corrosion or moisture damage from an autoclave. However, it takes relatively longer than steam sterilization [Sant'Ana et al., 2014].

Filtration Sterilization: This has been a method for physically removing microorganisms from liquid or air form. This process uses membrane filters with pore sizes too small for the microorganisms to pass through [18].

Filtration is also commonly used to sterilize heat-sensitive products such as protein solutions, vaccines, and some drugs. The pore size of the filters should be small enough to prevent the passage of microorganisms, for example, 0.22 μm or smaller.

Ionizing Radiation Sterilization: Ionizing radiation (e.g. γ -rays or electron beams) is used to kill microorganisms. Radiation causes mutations in the DNA of microorganisms, leading to cell death [Danyo et al., 2024].

Ionizing radiation can serve as a suitable alternative for the sterilization of heat-sensitive products and is widely applied in the sterilization of medical devices, packaging materials, and certain biopharmaceutical products [[Danyo et al., 2024].

The choice of sterilization method is based on the characteristics of the material to be sterilized, the type of product, the manufacturing method and regulations. Compliance studies should be conducted to verify the effectiveness of sterilization processes and continuous control of sterilization procedures should be ensured. This is essential for product and patient Safety [Jildeh et al., 2020].

Disinfection

Disinfection is the process of reducing the number of microorganisms on a surface or in an environment to an acceptable level or to eliminate their ability to cause disease [Gebel et al., 2013].

Unlike sterilization, disinfection does not kill all microorganisms; however, it reduces the risk of infection by reducing the number of pathogens. Disinfection methods include:

Chemical Disinfectants

Various chemical substances such as alcohols, chlorine compounds, iodine compounds, phenols, quaternary ammonium compounds provide disinfection by disrupting the cell structures of microorganisms or by inhibiting their metabolic processes. These disinfectants are widely used in cleaning surfaces, equipment and tools. Disinfectant selection should be made carefully according to the type of surface, level of contamination and targeted microorganisms [Sadiq et al., 2019].

UV Light: Ultraviolet (UV) light kills microorganisms by damaging their DNA or inhibits their ability to reproduce. UV light is effectively used in the

disinfection of air, water and surfaces. UV disinfection is widely used, especially in water treatment plants and air cleaning systems [Kciuk et al., 2020].

Filtration: Filtration is an important method used for both sterilization and particle removal. It works by passing a liquid or gas through a filter with pores that are too small for microorganisms and other particles to pass through [Cescon et al., 2020].

Filtration Methods

Filtration offers a variety of methods suitable for different applications.

Membrane Filtration: This is the process of separating particles and microorganisms using membrane filters with various pore sizes. Polymers used to multiplex membranes are usually made of polymer materials and are available in different pore sizes for various functions. This is also a method commonly used in pharmaceutical manufacturing and water treatment [O'brien et al., 2012].

Deep Filtration

This is a highly efficient method, a process in which microorganisms are adsorbed and trapped using a thick, porous material. Deep filters are usually made of cellulose, diatomaceous earth or other materials and are suitable for substances with high particle loads. This technique is particularly useful in pre-filtration stages and in the clarification of liquids with high particle content [Cescon et al., 2020].

Aseptic Processing

Aseptic processing refers to the handling and packaging of sterilized products in a sterile environment. When sterilization is not possible or the quality of the product would be compromised, aseptic processing must be relied upon. Aseptic processing in aseptic manufacturing area is a highly controlled and clean way to prevent contamination [Agalloco et al., 2014].

Aseptic Process Stages: Aseptic process consists of the following steps:

Sterile Environment: Aseptic processes are carried out using clean rooms or HEPA filtered isolators. In such environments, particle and microorganism levels are carefully controlled. Clean rooms and isolators are periodically cleaned and disinfected to reduce the risk of contamination.

Sterilization of Equipment and Materials: All equipment, tools and materials for aseptic processing must be sterile. This is achieved by appropriate sterilization methods such as autoclaving, dry heat sterilization, radiation or filtration. It is mandatory to regularly verify the sterility of the procedures.

Trained Personnel: Personnel involved in aseptic processing must be trained in sterility techniques and strictly comply with hygiene rules. Hand hygiene, clothing and behavior of personnel are extremely important in maintaining the sterility of the product [Agalloco et al., 2014].

Conclusion

Ensuring microbial safety in pharmaceutical production is possible with a comprehensive risk management and control strategy implemented at every stage of the production process, moving beyond an approach dependent on end-product tests alone. Although end-product tests in accordance with the standards set by pharmacopoeias provide a final verification of product safety, they may not always detect potential contamination due to sampling limitations. Therefore, risk assessment methods, determination of critical control points and adoption of continuous improvement principles are indispensable for pharmaceutical manufacturers to keep patient safety at the highest level. Ensuring microbial safety is a continuous and dynamic process that not only meets regulatory requirements but also fulfills the responsibility of protecting public health.

References

Agalloco J, Akers J, Kennedy A. Aseptic Processing: A Review of Current Industry Practice. *Pharmaceutical Technology* [Internet]. 2014; Available from: www.pharmtech.com

Alhazmi HA, Albratty M. Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies. *Pharmaceuticals*. MDPI; 2023.

ASLAN, İ., & KURT, A. A. (2024). Evaluation of the physical properties of an orodispersible tablet containing melatonin and pyridoxine HCl (Vitamin B6). *Journal of Research in Pharmacy*, 28(6).

Cescon A, Jiang JQ. Filtration process and alternative filter media material in water treatment. *Water (Switzerland)*. 2020;12.

Danyo EK, Ivantsova MN, Selezneva IS. Ionizing radiation effects on microorganisms and its applications in the food industry. *Foods and Raw Materials*. Kemerovo State University; 2024. p. 1–12.

DARMADY EM, HUGHES KE, JONES JD, PRINCE D, TUKE W. Sterilization by dry heat. *J Clin Pathol*. 1961;14:38–44.

Fajdek-Bieda A, Pawlińska J, Wróblewska A, Żwierzęło W, Łuś A, Klimowicz A. Antibacterial and Preservative Potential of Eugenol and Isoeugenol in Cosmetics: A Natural Solution for Product Stability. *Applied Sciences* (Switzerland). 2025;15.

Gebel, J., Exner, M., French, G., Chartier, Y., Christiansen, B., Gemein, S., ... & Sonntag, H. G. (2013). The role of surface disinfection in infection prevention. *GMS hygiene and infection control*, 8(1), Doc10.

Glevitzky M, Glevitzky I, Mucea-Ştef P, Popa M, Dumitrel GA, Vică ML. Integrated Risk Framework (IRF)—Interconnection of the Ishikawa Diagram with the Enhanced HACCP System in Risk Assessment for the Sustainable Food Industry. *Sustainability* (Switzerland). 2025;17.

Hossain MS, Balakrishnan V, Rahman NNNA, Sarker MZI, Kadir MOA. Treatment of clinical solid waste using a steam autoclave as a possible alternative technology to incineration. *Int J Environ Res Public Health*. 2012;9:855–67.

Kurt, A. A., & Ibrahim, B. (2024). New generation natural face cream formulation: development and in vitro evaluation. *Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi*, 11(4), 672-680.

ITO T, Wang H, Hwang SH, Wang B, Wang L, G S. Risk assessment for biopharmaceutical single-use manufacturing: A case study of upstream continuous processing. *Biologics*. 2023;84.

Javanmard S. An Overview of the Various Appropriate Types of Cell Lines for the Production of Monoclonal Antibodies. *Int J Pharm Investig.* 2023;13:381–92.

Jildeh ZB, Wagner PH, Schöning MJ. Sterilization of Objects, Products, and Packaging Surfaces and Their Characterization in Different Fields of Industry: The Status in 2020. *Physica Status Solidi (A) Applications and Materials Science.* John Wiley and Sons Inc; 2021.

Jouette S. European Pharmacopoeia Chapter 5.1.6 Alternative methods for control of microbiological quality. *EDQM Symposium on Microbiology.* 2017.

Kciuk M, Marciak B, Mojzych M, Kontek R. Focus on uv-induced dna damage and repair—disease relevance and protective strategies. *Int J Mol Sci.* MDPI AG; 2020. p. 1–33.

Kesik-Brodacka M. Progress in biopharmaceutical development. *Biotechnol Appl Biochem.* Wiley-Blackwell Publishing Ltd; 2018. p. 306–22.

Kurt, A. A., & Ibrahim, B. (2024). Development and Microbiological Evaluation of Natural Diaper Rash (Diaper Dermatitis) Cream Formulations. *Journal of Immunology and Clinical Microbiology*, 9(1), 1-11.

Kuystermans D, Al-Rubeai M. Biopharmaceutical Products from Animal Cell Culture. Springer International Publishing Switzerland. 2015;717–57.

Mohapatra S. Sterilization and Disinfection. *Essentials of Neuroanesthesia.* Elsevier; 2017. p. 929–44.

Montero Zamora J. Effect of temperature-time on sterilization process for a jacketed bioreactor system: Application of a Ratkowsky Nonlinear Model. *Revista Ingeniería.* 2018;28:63.

O'brien TP, Brown LA, Battersby DG, Rudolph AS, Raman LP. Large-Scale, Single-Use Depth Filtration Systems for Mammalian Cell Culture Clarification. *Bioprocess Int.* 2012.

Pashang R, Gilbride KA, Wenk J. Microbial Dynamics and Quality Monitoring in Biopharmaceutical Production. *ChemBioEng Reviews.* John Wiley and Sons Inc; 2024.

Sant'Ana AS. Physical Removal of Microfloras: Filtration. *Encyclopedia of Food Microbiology: Second Edition.* Elsevier Inc.; 2014. p. 36–41.

Saqib Ishaq M, Afsheen Z, Khan A, Khan A. Disinfection Methods. Photocatalysts - Applications and Attributes. IntechOpen; 2019.

Schneier M, Razdan S, Miller AM, Briceno ME, Barua S. Current technologies to endotoxin detection and removal for biopharmaceutical purification. *Biotechnol Bioeng.* John Wiley and Sons Inc.; 2020. p. 2588–609.

Suvikas-Peltonen E, Hakoinen S, Celikkayalar E, Laaksonen R, Airaksinen M. Incorrect aseptic techniques in medicine preparation and recommendations for safer practices: A systematic review. European Journal of Hospital Pharmacy . BMJ Publishing Group; 2017. p. 175–81.

Tang Z, Du Q. Mechanism of action of preservatives in cosmetics. *Journal of Dermatologic Science and Cosmetic Technology* [Internet]. 2024;1:100054. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2950306X24000529>

Chapter 4

Microbial Metabolism and Drug Interactions

Bashar IBRAHIM¹

Abstract

Microbial Metabolism Microbial metabolism (or metabolism) is the totality of biochemical reactions that are carried out by microorganisms for the purpose of survival, growth and replication. These processes allow microorganisms to draw nutrients from their environment and transform them into energy, produce building blocks and expel waste products. Microbial metabolism has been important for the pathogenesis of infectious diseases, the effectiveness of antimicrobial drugs, and drug metabolism. Drug biotransformation by complex microbial community (microbiota) present in the human body in particular has been implicated in changing the pharmacokinetic profile, thus influencing both drug efficacy and toxicity. This section will explore the fundamental principles of microbial metabolism, mechanisms of drug interactions, and clinical outcomes of these interactions in detail.

Keywords: Microbial Metabolism, Drug Interactions, Microbiota, Drug Resistance

¹ Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Süleyman Demire University, Isparta 23000 Turkiye. basharibrahim@sdu.edu.tr ORCID No: 0000-0003-3086-0995

Introduction

As a constantly evolving field bridging the realms of modern medicine and pharmacology, one such area of growing study is microbial metabolism and drug interactions. The elaborate biochemical activity of microorganisms in our bodies and in our environment influences our health directly and dramatically influences the efficacy and safety of the drugs that we use (Martinelli et al., 2024, Aslan et al., 2024, Torres-Carrillo et al., 2014). Thus, the understanding of microbial metabolism and drug interactions is essential for developing new therapeutic strategies, maximizing current treatments, and addressing global health issues such as antimicrobial resistance (Muteeb et al., 2023).

Microorganisms are fundamental to all life on Earth and play important roles in humans. In particular, the intestinal microbiota plays a key role in a wide range of biochemical processes, including immune system regulation, digestion, and vitamin synthesis. Bacterial genus While most microorganisms are harmless, some can cause infection. Antibiotics used to treat such infections target the metabolic pathways of these pathogens. Therefore, recognizing the effects of drugs on microbial metabolism and the ability of microorganisms to acquire resistance mechanisms is a critical aspect of drug development (Kazi et al., 2021, Thursby et al. 2017, Uddin et al., 2021).

The system of interaction of pharmaceuticals with microbial metabolism can strengthen or weaken the effectiveness of the respective pharmaceuticals or lead to adverse toxic effects. Some bacterial strains are known to metabolise drugs into inactive compounds. Other times, bacteria can make drugs more toxic. Moreover, microorganisms can acquire drug resistance by mutating the molecule that the drug targets, such as an enzyme or receptor. Antimicrobial resistance mechanisms spoil the effectiveness of antimicrobial agents and therefore hinder the treatment of infections, highlighting the need for the development of novel drugs (Wilson et al., 2017, Wang et al., 2024, C Reygaert et al., 2018).

Genomics of the human gut microbiota and its implications for understanding microbial metabolism and interactions with pharmaceutical agents have practical significance for both basic science and clinical practice. Research in this field can help lead to new strategies to enhance the efficacy and safety of drugs, surmount antimicrobial resistance, and adopt personalised medicine approaches 3. This study highlights the critical need for a better understanding of microbial metabolism and drug interactions if we are to enhance future health outcomes. In this light, the current chapter will hence perform an extensive overview of the general rationale of microbial metabolism, drug-microbe interaction potentials as well as approaches, and the clinical implications of such engagements.

Basic Principles of Microbial Metabolism

Microbial metabolism is a series of biochemical processes in which microorganisms use a complex and interactive series of biochemical reactions to maintain their vitality, growth, and reproduction. These metabolic processes are key to allowing microbial cells to carry out the most basic functions of life. Microbial metabolism is not only responsible for the production of energy, the synthesis of new cellular building blocks, but also, the activation of adaptation to environmental constraints. Microbial metabolism can thus be divided into two main processes: catabolism, used to reduce large molecules to energy; and anabolism, the complex molecules produced from smaller ones. Enzymes, which speed up and guide specific chemical reactions, help regulate these metabolic pathways. Thus, understanding how microbial metabolism impacts the environment and factors into biogeochemical cycles within the biosphere is critical (Ezembra et al., 2022).

Catabolism: Energy Production And Production Of Molecular Building Blocks

Catabolism is described as the conversion of complex organic molecules (carbohydrates, proteins, lipids, etc.) into simpler molecules. This is coupled with the release of energy, which is stored in energy carrier molecules (e.g. adenosine triphosphate (ATP)). In addition, catabolism gives the monomers (amino acids, sugars, fatty acids, etc.) needed for anabolism. Additionally, microorganisms employ multiple metabolic pathways for catabolism (Escoll et al., 2019).

Respiration

Aerobic respiration is a catabolic pathway in which O₂ is the final electron acceptor and large amounts of ATP are produced. Anaerobic respiration, in contrast, is where other inorganic molecules like nitrate, sulfate or carbon dioxide, are used instead of oxygen. This gives a lower yield of ATP than aerobic respiration.

Fermentation

The process by which chemical reactions occur without oxygen. This is known as a catabolic pathway that takes place in the absence of oxygen. During the fermenting process, organic molecules (usually sugars) are broken down to some degree to generate organic acids; or alcohols, like lactic acid, ethanol, and acetic acid. Although the amount of net ATP produced per mole of the substrate is greater in respiration compared to fermentation, this pathway can serve as the only source of energy for some microbes.

It is evident that each microorganism type possesses a distinct catabolic profile, a characteristic that facilitates adaptation to the environment and utilisation of specific resources. For instance, certain bacterial species are capable of metabolizing only specific sugars, whereas others possess the capacity to degrade complex polysaccharides or aromatic compounds (Wang et al., 2021).

Anabolism: Synthesis Of Cell Components

Anabolism is defined as the process of synthesising complex molecules, including proteins, nucleic acids, lipids and polysaccharides. These are synthesised using the energy and molecular building blocks produced during catabolism. These processes are necessary for cell growth, repair, and reproduction. Anabolism is characterised by a series of chemical reactions that require energy and are catalyzed by enzymes (Pang et al. 2014).

Protein Synthesis

A process in which amino acids bond with peptide bonds to create proteins. Proteins make up the cell structure, catalyze enzymes, do transport work, and signal to other cells.

Nucleic acid synthesis

The joining of nucleotides through phosphodiester bonds forms DNA and RNA. DNA carries genetic information, while RNA plays a crucial role in protein synthesis.

Lipids Synthesis

The process of fatty acids binding with glycerol to create triglycerides, phospholipids, and other lipids. Lipids make up the structure of cell membranes, energy storage, and signaling.

Polysaccharide Synthesis

The process in which sugars combine with glycosidic bonds to form polysaccharides such as starch, cellulose and chitin. Polysaccharides form the structure of cell walls, store energy and determine the surface properties of cells.

The anaerobic potential of microbes depends on the environmental conditions and nutrient substrates available to them. Certain microorganisms can produce all the amino acids and vitamins they need, while others must get them from the environment (Sharma et al., 2024).

Microbial Metabolism of Drugs

Given that microorganisms can metabolise drug molecules by several enzymatic reactions when they have access to pharmaceutical compounds, it is already a well-recognized fact. Such metabolism by the gut microbiome may have a pronounced impact on the pharmacology and toxicology of the drug. The metabolic process can produce drug inactivation by diminishing the therapeutic action of the drug; conversely, activation can occur whereby an inactive prodrug is made active. In addition, in some cases, the produced metabolites by microbial metabolism may be even more toxic than the original drug molecule. This phenomenon can cause adverse effects and treatment failure. The most common reactions involve enzymatic reactions able to change the chemistry of the drug and thus also its ADME (absorption, distribution, metabolism, and excretion) profile. As such, knowledge of microbial drug metabolism is critical to modern drug-developing practices and personalized medicine (Liu et al., 2022, Dodd et al., 2020).

Reduction Reactions

Reduction (the addition of electrons to a molecule) is a key element of microbial metabolism. Bacteria are a vital player in the biotransformation of drugs and will reduce nitro (-NO₂) groups and azo (-N=N-) groups from drugs. For instance, azo reductases cleave azo bonds in azo dyes and drugs (e.g., sulfasalazine) into small molecules. This is important for the activation of sulfasalazine through the formation of its active component 5-aminosalicylic acid (5-ASA) (Wilson et al., 2017, Wang et al., 2021). Nitro-reductase enzymes can also reduce drugs bearing a nitro group to amines (nitro reduction), changing the function of the drug, or forming toxic metabolites. Such reduction reactions are widespread in gut microbiota, specifically those that proliferate under anaerobic conditions and can lead to substantial alterations in the pharmacokinetic and pharmacodynamic features of pharmaceuticals.

Oxidation Reactions

Oxidation is the loss of electrons from a molecule, and this step is often seen in microbial metabolism. Cytochrome P450 (CYP450) enzymes are central to drug metabolism in mammals, though similar oxidation reactions have been documented in some bacterial species. These bacterial CYP450s can catalyse the hydroxylation, epoxidation, and dealkylation of drugs. These reactions can cause the drug to be less active (referred to as inactivation), or to become more active (referred to as activation), or to produce toxic metabolites. Bacterial oxidation

reactions play a crucial role in this process because they can increase water solubility and aid the elimination of drugs containing complex aromatic rings.

Hydrolysis Reactions

The breaking of chemical bonds through addition of water to a molecule is hydrolysis, another essential reaction often regarded in microbial metabolism. For enzyme-mediated drug hydrolysis, microbial esterases and amidases are known to catalyze the inactivation of drugs by hydrolyzing ester and amide bonds, respectively. Again local anesthetics like procaine undergo hydrolysis by esterases by intestinal bacteria, leading to inactivation. Likewise, a few penicillins (beta-lactam antibiotics) lose their antibacterial activity by hydrolyzing by bacterial beta-lactamase enzymes. Drug hydrolysis reactions are significant in drug metabolism for drugs that contain ester or amide bonds, and they can greatly impact the drug's efficacy and toxicity.

Konjugasyon Reaksiyonları

Conjugation reactions involve attachment of polar molecules such as electronic acid, sulfate or acetyl groups to drugs. These reactions make drugs more water-soluble and help the drug to be excreted. Mammalian drug metabolism commonly involves conjugation reactions such as glucuronidation, salvation and acetylation. Intestinal microbiota can liberate these conjugates to resupply drugs. The resulting conjugation can facilitate intrahepatic circulation, extending the residence time of drugs in the body and their potential toxicity. More specifically, glucuronidation and salvation may be reversed by microbial conjugation enzymes, resulting in drug reactivation or toxic metabolite formation.

Other metabolic reactions

Microorganisms perform a wide variety of other metabolic reactions, including decarboxylation, deamination and demethylation in addition to the basic reactions described above. One type of organic reaction is decarbonization, which is the removal of the carboxyl group (COOH) from a molecule — some microbes have the ability to decarboxylate amino acids, resulting in the production of biogenic amines (e.g. histamine, tyramine). These amines could act on drugs and trigger side effects. Deamination refers to the removal of the amino group (NH₂) from a molecule, and certain bacteria can deaminate amines, generating ammonia and other metabolites. Demethylation is the stripping of the methyl group (CH₃) from a molecule, and some types of bacteria are certainly able to methylate drugs, changing their activity. These metabolic reactions may

change the pharmacokinetic and pharmacodynamic properties of the drug and modify clinical outcomes.

Mechanisms Of Microbial Interference

Microbial drug interactions can occur through direct or indirect pathways (Zhao et al., 2023).

Direct Interaction Mechanisms

Metabolism of Drugs by Microbial Enzymes

The main mechanism for direct interaction are microbial enzymes which metabolize drugs. As described earlier, the drugs can be metabolized by bacteria via several different enzymatic reactions (reduction, oxidation, hydrolysis, and conjugation). Such metabolism can lead to decreased activity of the drug (inactivation), increased activity of the drug (activation), or the formation of toxic metabolites. Dose reductions of digoxin may be due to bacterial metabolism by *Escherichia coli*, which can completely deactivate the cardiac glycoside activity of this drug, resulting in treatment failure. On the other hand, intestinal bacteria convert sulfasalazine to 5-ASA, leading to the anti-inflammatory effect of the drug. Direct metabolic interactions such as these can play a significant role in clinical outcomes by modifying the pharmacokinetic profile (absorption, distribution, metabolism, excretion - ADME) of drugs.

Effect of drugs on microbial growth

Another parameter of direct interactions is the impact of drugs on microbial growth. Antibiotics work either by killing target bacteria (bactericidal) or inhibiting their growth (bacteriostatic). This is an important effect in the treatment of infectious diseases. But the indiscriminate use of antibiotics can disturb the intestinal microbiota and cause symbiosis. This, in turn, can engender the selection of resistant bacteria, the outgrowth of opportunistic pathogens, as well as an increased susceptibility towards diseases like *Clostridium difficile* infection. But it is not just antibiotics that can influence and suppress microbial growth; a number of other drugs too have direct effects on microbes. For instance, proton pump inhibitors (PPIs) can change intestinal pH by decreasing gastric acid and can change microbial composition. This can contribute to small intestinal bacterial overgrowth (SIBO) and other gastrointestinal issues.

Microbial Metabolites Modulate Drug Action

Microbial metabolites directly or indirectly modulate drug actions. Dietary fiber is fermented by intestinal bacteria to yield short-chain fatty acids (Sofas),

which are beneficial to intestinal health. Sofas have the potential to improve intestinal barrier properties, decrease inflammation and modulate the immune response. Certain types of sofas can influence the absorption and metabolism of drugs. For instance, bitrate has been found to affect how much of some drugs are absorbed or not absorbed. Bile acids are similarly synthesized in the liver and metabolized by intestinal bacteria. Bile acids can also undergo deconjugation and epimerization by intestinal bacteria, which may contribute to the diversity of the bile acid pool. These changes can make it harder for drugs to be absorbed and metabolized.

Indirect Interaction Mechanisms

Change in microbiota composition

Drugs can indirectly cause drug interactions through modification of the microbiota. The culprits that most alter the composition of the microbiota are antibiotics. Antibiotic utilization can destroy susceptible germs, select for resistant pathogens, and augment opportunistic organisms. This can disturb gut microbiota homeostasis and impact metabolism and efficacy of other drugs. One example includes the use of antibiotics which can enhance the effect of digoxin by lowering levels of *Eggerthella lenta*, which inactivates digoxin. Likewise, chemotherapeutic drugs and immunosuppressants can change the composition of the microbiota and cause drug interactions (Weersma et al., 2020).

Modulation of the Immune System

Through this modulation, the microbiota also indirectly contribute to drug interactions through the immune system. Microbiota is well known to modulate the development and functioning of immune cells. There are many ways that the microbiota drive intestinal immunity, including stimulating Immunoglobulin A (IgA) production, modulating T cell activation, and regulating inflammatory cytokine production. Abstract: The immune response can be modulated by drugs, and the composition of the microbiota can impact drug action. For instance, PD-1 inhibitors, which are immunotherapeutic agents, may be effective pending the composition of the microbiota. Some work has suggested that specific bacteria might boost immunotherapy response (Zheng et al., 2020).

Clinical Results And Examples

Microbial drug interactions can lead to a variety of clinical outcomes by altering the efficacy, safety, and pharmacokinetics of drugs. These outcomes can range from treatment failure to increased toxicity, from the development of drug resistance to unexpected side effects. Detailed study of the clinical implications

of these complex interactions between the microbial ecosystem and drugs is vital to developing better treatment strategies and improving patient outcomes (Zhao et al., 2023, Hitchings et al., 2019).

Altered drug efficacy

The effect of microbial metabolism on drug efficacy can either enhance or diminish the desired therapeutic effect with a profound impact on treatment outcome. Prodrugs yielding an active form due to microbial activation lead to therapeutic effects. For instance, with sulfasalazine, intestinal bacteria convert it into the active anti-inflammatory 5-aminosalicylic acid (5-ASA). This conversion is essential for the action of sulfasalazine as a treatment for inflammatory bowel disease. But microbial metabolism could diminish the treatment's effectiveness. Reduction of digoxin to an inactive state by the gut microbe *Escherichia coli* can abrogate the cardiac glycoside activity of the drug, which is associated with treatment failure. Microbial enzymes also carry the same potential for hydrolysis or conjugation of drugs rendering the drug inactive and void of therapeutic activity. Hence, microbial metabolism, affecting drug efficacy, is an important parameter impacting treatment regimen design (Zheng et al., 2020).

Increased toxicity

Drugs are transformed into toxic metabolites through microbial metabolism, which can lead to increased toxicity. Paracetamol (acetaminophen) is a popular analgesic and antipyretic. N-acetyl-p-benzoquinoneimine (NAPQI) is a hepatotoxic metabolite generated by paracetamol metabolism within the liver. Under normal circumstances NAPQI gets detoxified via glutathione conjugation. Though, in overdose, glutathione is depleted and NAPQI leads to hepatic injury. Some gut microbiota also convert paracetamol to NAPQI and enhance toxicity. Likewise, when some other toxic metabolites are produced by microbial metabolism; for example, it can damage the liver, kidneys, or other organs. On this account, it is relevant to pay attention to the role of microbial metabolism in drug toxicity assessment (Mazaleuskaya et al., 2015).

Development of Drug Resistance

This overuse and misapplication select for resistant strains of bacteria. Mechanisms of resistance can occur by removing the drug from its target site, inactivation of the drug, or by modifying the drug's target molecule (Martinelli et al., 2024). Bacterial enzymes also eliminate antibiotics. Beta-lactamase enzymes, for instance, hydrolyse beta-lactam antibiotics (for example,

penicillins, cephalosporins) to abrogate antibiotic activity. Likewise, aminoglycoside modifying enzymes (AMEs), modify aminoglycoside antibiotics by adding nucleotide moieties to the core to decrease antibiotic activity. Bacteria could also mutate target molecules of antibiotics (e.g. ribosomes, DNA gyrase) such that they no longer bind the antibiotic. The emergence of drug resistance is the leading problem for treating infectious disease, thus prompting the needs for developing novel antibiotics and implementing rational antibiotic use strategies (Chis et al., 2022).

Emergence of Drug Side Effects

Metabolites resulting from microbial metabolism can cause drug side effects. Levodopa is a drug used to treat Parkinson's disease. Levodopa is a precursor to dopamine and is converted to dopamine in the brain, which compensates for dopamine deficiency. However, some intestinal bacteria can convert levodopa to dopamine. Dopamine cannot cross the blood-brain barrier and can cause peripheral side effects (e.g., nausea, vomiting, hypotension). Therefore, overgrowth or activity of intestinal bacteria in patients receiving levodopa therapy may increase the severity of side effects. Similarly, other metabolites resulting from microbial metabolism can cause gastrointestinal discomfort, skin rashes, or other side effects (Xu et al.,2022).

Increased Susceptibility to Diseases

Disruption of the microbiota composition results in an increased susceptibility to diseases due to antibiotic use. *Clostridium difficile* infection (CDI) represents a high burden infection related to the use of antibiotics. Antibiotics disturb the balance of the intestinal microbiota, thereby allowing *C. difficile* spores to germinate and toxins to be produced. Toxins produced by *C. difficile* damage the intestinal mucosa and lead to symptoms like diarrhea, abdominal pain, and colitis. In serious cases, CDI can be fatal. Antibiotic use also increases the susceptibility to other diseases including allergic disease, autoimmune disease, and metabolic diseases. Thus, correct use of antibiotics and strategies for microbiota restoration is essential to help mitigate the harmful effects of antibiotic therapies across the microbiome (Singh et al., 2025).

EXAMPLE DRUG INTERACTIONS

The clinical significance of microbial drug interactions can be better understood through specific examples of interactions between various drugs and microorganisms. These examples demonstrate the profound effects of microbial

metabolism on drug efficacy, toxicity, and pharmacokinetics, and highlight the importance of developing personalized treatment strategies (Wang et al., 2021).

Digoxin and Eggerthella lenta Interaction

Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation. It works by inhibiting the sodium-potassium ATPase pump, which increases the force of contraction of the heart. But one intestinal bacterium, *Eggerthella lenta*, is able to reduce digoxin to an inactivated metabolite, called dihydrodigoxin (DHD). This reduction reaction abolishes the cardiac glycoside site activity of digoxin which could lead to treatment failure. In addition, *E. lenta* populations show considerable interindividual variability, which can translate to significant differences in digoxin pharmacokinetics. In certain patients, *E. lenta* can metabolize as much as 70% of digoxin and markedly lower the serum concentration of the drug. By decreasing the *E. lenta* population, antibiotics may potentiate the digoxin effect. This can elevate the risk of digoxin toxicity, which may necessitate careful dose adjustment. This interaction highlights the potential influence of microbial metabolism on drug efficacy and hints at how the individual microbiota composition could have an impact, on the drug response (Haiser et al., 2014, Dong et al., 2022).

Methotrexate and Microbiota Interaction

Methotrexate (MTX) is a folic acid analogue used in the management of cancer, autoimmune diseases (e.g. rheumatoid arthritis, psoriasis), and ectopic pregnancy. Intestinal metabolism of MTX by some bacteria results in loss of activity. Moreover, in MTX the intestinal mucosa may be affected with consequent dysbiosis and enhanced intestinal permeability. It also may refer to the leakage of bacterial products (such as lipopolysaccharide - LPS) into systemic circulation and inflammation associated with increased intestinal permeability. This can magnify the side effects of MTX (e.g. mucositis, hepatotoxicity). Little evidence suggests that administering probiotics may alleviate MTX-induced side effects and enhance treatment response. However, this effect of probiotics on MTX interaction may differ based on probiotic strain, the dose, and the duration of treatment (Koźmiński et al., 2020, Kamel et al., 2023).

Sulfasalazine and Intestinal Bacteria Interaction

Sulfasalazine is a drug used in the treatment of inflammatory bowel diseases (IBD) (eg, Crohn's disease, ulcerative colitis) and rheumatoid arthritis. Sulfasalazine is made up of antimetabolite sulfapyridine and 5AMSA (5-aminosalicylic acid). Sulfasalazine is inactive, and however, intestinal bacteria

(mostly in the colon) cleave sulfasalazine via azo reductase enzymes into sulfapyridine and 5-ASA. 5-ASA is an active ingredient that possesses anti-inflammatory action and acts locally on the intestinal mucosa. Sulfapyridine is absorbed systemically and may account for some of the agranulocytosis side effects (e.g., nausea, vomiting, headache). It is lost if intestinal bacteria cannot reduce sulfasalazine to its active metabolite, 5-ASA. Antibiotics may interfere with this conversion and can reduce the efficacy of sulfasalazine. Sulfasalazine metabolism requires certain types of bacteria, and in some patients, the absence of these specific types of bacteria can lead to inadequate therapeutic effectiveness of the drug (Ye et al., 2024).

Interaction of Immunotherapeutic Agents and Microbiota

Immunotherapeutic agents, especially PD-1/PD-L1 inhibitors, have greatly progressed in cancer therapy in recent years[4][5][6]. Nonetheless, not every patient responds to immunotherapy, and the influence of microbiome composition on the response to immunotherapy is becoming increasingly clear. Results of several studies suggest that some gut bacteria (e.g. Akkermansia muciniphila, Bifidobacterium spp.) The response to immunotherapy can be improved by Bacteria can modulate the immune system, change the tumor microenvironment, and improve the efficacy of immunotherapy. Microbiota composition is disturbed by antibiotic use leading to less response to immunotherapy. Some studies have suggested that cancer patients taking antibiotics do not respond as well to immunotherapy. One such potential strategy under investigation is fecal microbiota transplantation (FMT) to potentiate responses to immunotherapy (Shiravand et al., 2022).

Future Perspectives

Future research should focus on several important areas to unravel the complexity of these interactions, develop new treatment strategies, and advance personalized medicine approaches.

Better Understanding the Effects of Drugs on Microbiota

A better understanding of how the composition and function of the microbiota is affected by different drugs may help in rationalising drug use and ameliorating side effects. This should cover the impact of not only antibiotics but also other frequently consumed drugs, such as cardiovascular drugs, antidiabetics, proton pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs) microbiota. Advanced technology options, including metagenomics, metatranscriptomics, and metabolomics, can also be used to

evaluate the effects of drugs on the microbiota, and they may facilitate the identification of changes in microbial composition, gene expression, and metabolite profiles. They should, furthermore, involve long-term cohort studies that evaluate the effects of drugs on the microbiota and the possible implications of such effects on human health. A more thorough understanding of how drugs affect the microbiota may guide drug development strategies with microbiota-sparing or -restorative actions (Dharmarathne et al., 2024).

Determination of the Effects of Microbial Metabolism on Drug Efficacy and Toxicity

Increased knowledge regarding the mechanisms by which drugs are activated or converted into inactive metabolites through microbial metabolism may open avenues for personalized medicine. Since each individual's microbiota composition and metabolic capacity differ, so does the microbial metabolism of drugs. This underscores the need for tools to profile individual microbiota and predict drug metabolism by the microbiota. This might involve creating a pharmacomicobiomics approach, again, reminiscent of the pharmacogenomics approach. The field of pharmacomicobiomics seeks to tailor dosing and choice of drugs based on the profile of an individual's microbiota. Moreover, in vitro and in vivo toxicology studies were necessary to investigate the influence of microbial metabolism on the drug toxicity. These studies may also shed light on microbial enzymes that are involved in drug to toxic metabolite conversion in addition to the action of these toxic metabolites on their target organs (Alashry et al., 2024).

Management of Drug Interactions by Microbiota Modulation

Various methods of modulating the microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), show potential to enhance drug effectiveness, as well as mitigate its toxic effects. Probiotics are defined as live microorganisms that provide health benefits, balancing the intestinal microbiota. Probiotics have been demonstrated to reduce antibiotic-associated diarrhoea, ameliorate inflammatory bowel disease symptoms, and boost immunotherapy response. Prebiotics, fermentable polysaccharides, act as dietary fibers that are catabolized by gut microorganisms (Kazi et al., 2021, Thursby et al. 2017, Uddin et al., 2021). Prebiotics can improve composition and function of intestinal microbiota and metabolic health. FMT is the transfer of healthy donor fecal microbiota to a recipient. FMT is a promising therapy in the treatment of recurrent *Clostridium difficile* infections and is currently being investigated as a possible approach to treat a variety of other diseases. Future randomized

controlled trials are required to study the effect of microbiota modulation on drug interactions. Such studies may inform microbiota modulation to enhance drug action, decrease side effects and improve personalized therapy (Wang et al., 2024).

Consideration of Microbial Metabolism in Drug Design

In the context of drug design, one of the goals in drug discovery development is making drugs resistant to microbial metabolism, thereby enhancing drug effectiveness and lowering adverse effects. Advancements in drug chemistry and pharmaceutical formulation may help in the development of drugs that are more resistant to microbial metabolism. For instance, by modifying the chemical structure of drug molecules to avoid their metabolism by microbial enzymes or enhancing drug absorptions into the intestine and limiting their exposure to microbial metabolism. Targeted drug delivery systems can also be developed where drugs are delivered directly to targeted site (tumor, inflamed tissues and etc.). These systems may provide lower exposure to systemic circulation and microbial metabolism of the drug. Designing drugs from a perspective of microbial metabolism can result in better, safer, more personalized drugs¹.

Use of High-Throughput Screening and Bioinformatics Approaches

It is crucial to utilize high-throughput screening (HTS) and bioinformatics methods for detecting and characterizing microbial drug interactions. HTS can be employed to quickly assess thousands of compounds for effects on microbial growth, metabolism, or drug interactions. For instance, these bioinformatics approaches show excellent performance in analyzing metagenomics, metatranscriptomics, and metabolomics data and predicting microbial drug interactions. Machine learning and artificial intelligence are involved in using advanced bioinformatics to anticipate drug interactions with microbes, opening up possibilities for drug design. Combination use of HTS and bioinformatics methodologies may allow faster identification and characterization of microbial drug interactions ⁴⁰.

Conclusion

Microbial metabolism significantly contributes to drug efficacy, toxicity and the development of resistance. The gut microbiota modulates the bioavailability, pharmacokinetics and pharmacodynamics of drug therapy; thus, drug-microbiota interactions can majorly affect therapeutic outcomes. Microbial enzymes can also convert drugs to active metabolites, inactivate them, or result in toxic byproducts that may give rise to unpredictable responses to drugs,

increasing the likelihood of adverse effects (Martinelli et al., 2024). In addition, much use of these antimicrobial drugs drives the evolution of microbial resistance mechanisms, resulting in treatment failure and significant impacts on public health. Hence, it is important to comprehend the complexity of drug-microbiota interactions to enable and promote rational use of drugs, optimize personalized medicine approaches, and aid in the design of new drug development strategies. These approaches can also be promising strategies aiming to modulate microbiota composition and metabolic activity, thereby improving drug efficacy, reducing toxicity and/or delaying the development of resistance. Research continues in this area across various disciplines (pharmacology, microbiology, metabolomics and genetics) and can be developmental for advancing new therapeutics with substantial opportunities to address human health.

References

Aslan, İ., Çelebi, L. T., Bursalioğlu, E., Çakıcı, B., Aydin, M. A., Ibrahim, B., & Kurt, A. A. (2024). Novel microbiome friendly purifying oil cleanser formulation with oil-soluble postbiotics. *Journal of Immunology and Clinical Microbiology*, 10(1), 1-2.

Martinelli F, Thiele I. Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities. Vol. 16, Gut Microbes. Taylor and Francis Ltd.; 2024.

Alashry, M. (2024). The Impact of The Microbiome on Drug Efficacy. Available at SSRN 4948954.

C Reygaert W. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol [Internet]. 2018;4(3):482–501. Available from: <http://www.aimspress.com/article/10.3934/microbiol.2018.3.482>

Chiş AA, Rus LL, Morgovan C, Arseniu AM, Frum A, Vonica-țincu AL, et al. Microbial Resistance to Antibiotics and Effective Antibiotherapy. Vol. 10, Biomedicines. MDPI; 2022.

Dharmarathne G, Kazi S, King S, Jayasinghe TN. The Bidirectional Relationship Between Cardiovascular Medications and Oral and Gut Microbiome Health: A Comprehensive Review. Vol. 12, Microorganisms. Multidisciplinary Digital Publishing Institute (MDPI); 2024.

Dodd D, Cann I. Tutorial: Microbiome studies in drug metabolism. *Clin Transl Sci*. 2022 Dec 1;15(12):2812–37.

Dong X, Guthrie BGH, Alexander M, Noecker C, Ramirez L, Glasser NR, et al. Genetic manipulation of the human gut bacterium *Eggerthella lenta* reveals a widespread family of transcriptional regulators. *Nat Commun*. 2022 Dec 1;13(1).

Escoll P, Buchrieser C. Metabolic reprogramming: an innate cellular defence mechanism against intracellular bacteria? Vol. 60, *Current Opinion in Immunology*. Elsevier Ltd; 2019. p. 117–23.

Ezembia, T. L. G. A., & Ezenwa, L. L. (2022). Copyright© 2022 Dr. Chinyere Constance Ezembia.

Haiser HJ, Seim KL, Balskus EP, Turnbaugh PJ. Mechanistic insight into digoxin inactivation by *Eggerthella lenta* augments our understanding of its pharmacokinetics. *Gut Microbes*. 2014 Jan 23;5(2):233–8.

Hitchings R, Kelly L. Predicting and Understanding the Human Microbiome's Impact on Pharmacology. Vol. 40, *Trends in Pharmacological Sciences*. Elsevier Ltd; 2019. p. 495–505.

Kamel WH, Marwa ;, Ali F, Afifi SH. HISTOPATHOLOGICAL AND BIOCHEMICAL STUDIES OF METHOTREXATE

HEPATOTOXICITY ON ALBINO RATS [Internet]. Vol. 69, Assiut Veterinary Medical Journal Assiut Vet. Med. J. 2023. Available from: www.aun.edu.eg

Kazi Madina Maraz, Ruhul Amin Khan. An overview on impact and application of microorganisms on human health, medicine and environment. *GSC Biological and Pharmaceutical Sciences*. 2021 Jul 30;16(1):089–104.

Koźmiński P, Halik PK, Chesori R, Gniazdowska E. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Vol. 21, *International Journal of Molecular Sciences*. MDPI AG; 2020.

Liu K, Sun Q, Liu Q, Li H, Zhang W, Sun C. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. Vol. 154, *Biomedicine and Pharmacotherapy*. Elsevier Masson s.r.l.; 2022.

Mazaleuskaya LL, Sangkuhl K, Thorn CF, Fitzgerald GA, Altman RB, Klein TE. PharmGKB summary: Pathways of acetaminophen metabolism at the therapeutic versus toxic doses. *Pharmacogenet Genomics*. 2015 Jul 22;25(8):416–26.

Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Vol. 16, *Pharmaceuticals*. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

Pang G, Xie J, Chen Q, Hu Z. Energy intake, metabolic homeostasis, and human health. *Food Science and Human Wellness*. 2014 Sep 1;3(3–4):89–103.

Sharma R, Garg P, Kumar P, Bhatia SK, Kulshrestha S. Microbial fermentation and its role in quality improvement of fermented foods. Vol. 6, *Fermentation*. MDPI AG; 2020.

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Vol. 29, *Current Oncology*. MDPI; 2022. p. 3044–60.

Singh C, Singh A, Singh D, Upadhyay R. Potential therapeutic solution for *Clostridioides difficile* infection: Current scenario and future prospects. Vol. 24, *Medicine in Microecology*. Elsevier B.V.; 2025.

Thursby E, Juge N. Introduction to the human gut microbiota. Vol. 474, *Biochemical Journal*. Portland Press Ltd; 2017. p. 1823–36.

Torres-Carrillo N, Martínez-López E, Torres-Carrillo NM, López-Quintero A, Moreno-Ortiz JM, González-Mercado A, et al. Pharmacomicobiomics and Drug–Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy.

Vol. 24, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran T Bin, et al. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Vol. 14, Journal of Infection and Public Health. Elsevier Ltd; 2021. p. 1750–66.

Wang S, Ju D, Zeng X. Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era. Vol. 12, Biomedicines. Multidisciplinary Digital Publishing Institute (MDPI); 2024.

Wang Y, Wu J, Lv M, Shao Z, Hungwe M, Wang J, et al. Metabolism Characteristics of Lactic Acid Bacteria and the Expanding Applications in Food Industry. Vol. 9, Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A.; 2021.

Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Vol. 69, Gut. BMJ Publishing Group; 2020. p. 1510–9.

Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Vol. 179, Translational Research. Mosby Inc.; 2017. p. 204–22.

Xu K, Sheng S, Zhang F. Relationship Between Gut Bacteria and Levodopa Metabolism. Curr Neuropharmacol. 2022 Oct 20;21(7):1536–47.

Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z. Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database. Front Pharmacol [Internet]. 2024 Sep 12;15. Available from: <https://www.frontiersin.org/articles/10.3389/fphar.2024.1452300/full>

Zhang S, Liu K, Liu Y, Hu X, Gu X. The role and application of bioinformatics techniques and tools in drug discovery. Vol. 16, Frontiers in Pharmacology. Frontiers Media SA; 2025.

Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Vol. 8, Signal Transduction and Targeted Therapy. Springer Nature; 2023.

Zheng C chao, Gao L, Sun H, Zhao XY, Gao Z qing, Liu J, et al. Advancements in enzymatic reaction-mediated microbial transformation. Vol. 10, Heliyon. Elsevier Ltd; 2024.

Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Vol. 30, Cell Research. Springer Nature; 2020. p. 492–506.

Chapter 5

Design and Analysis of Bioavailability/Bioequivalence Studies

Ahmet Arif KURT¹

Abstract

Bioavailability (BA) and bioequivalence (BE) studies play a critical role in drug development and regulatory approval processes. These studies aim to evaluate how quickly and effectively a drug is absorbed (bioavailability) and whether different formulations have comparable pharmacological effects (bioequivalence). BA/BE studies are essential for optimizing drug formulations, comparing alternative administration routes, and ensuring the reliability of generic drugs. This chapter discusses the core principles of designing and analyzing these studies. Study design encompasses the selection of volunteers or patients, drug administration protocols, sampling strategies, and the accuracy of analytical methods. The analysis phase focuses on pharmacokinetic parameters (AUC, Cmax, Tmax) and statistical evaluations. The quality of data obtained from these studies heavily depends on the rigor of study design and analytical methods. When effectively implemented and accurately analyzed, BA/BE studies provide a robust scientific foundation for assessing the efficacy, safety, and therapeutic equivalence of drug therapies, ultimately enhancing patient safety and optimizing treatment outcomes.

Keywords: Bioavailability, Bioequivalence, Drug Development, Study Design, Drug Formulation

¹ Süleyman Demirel University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Isparta, Türkiye; ahmetkurt@sdu.edu.tr, ORCID No: 0000-0002-3490-0192

Introduction

Bioavailability (BA) and bioequivalence (BE) studies are cornerstones of modern drug development processes. These studies provide critical information to establish the therapeutic efficacy and safety of a drug, serving as the foundation for optimizing drug formulations, comparing administration routes, and licensing generic drugs [Stielow et al., 2023]. While BA refers to the rate and extent at which a drug is absorbed into systemic circulation from the site of administration, BE measures whether different formulations of the same drug at the same dose yield comparable bioavailability profiles. Consequently, these concepts are fundamental in managing pharmacokinetic behavior and therapeutic equivalence of drugs within the body [Chow SC.,2014].

The quality and reliability of the generated data are predominantly influenced by the design of BA and BE studies. However, numerous confounding factors must be considered during study design, including the selection of an appropriate population of volunteers or patients, drug administration methods, dosage, sampling times, specificity and sensitivity of analytical methods, statistical analyses of data, and ethical considerations [Pawar et al., 2021]. A well-designed BA/BE study produces clinically meaningful data that accurately characterize a drug's pharmacokinetic profile [Patel et al., 2020].

Pharmacokinetic data must be meticulously examined in BA/BE analyses. Key pharmacokinetic parameters include the area under the plasma concentration-time curve (AUC), the maximum plasma concentration (Cmax), and the time to reach this maximum concentration (Tmax). These parameters are used to determine the bioequivalence of two drug formulations. Statistical analysis plays a critical role in interpreting data from BA/BE studies [Zuo et al., 2024]. Typically, two formulations are considered bioequivalent if their AUC and Cmax values fall within a predetermined confidence interval, commonly set at 80%-125%. Appropriate application of statistical methods ensures objective and scientifically valid outcomes [Lynggaard et al., 2024].

Properly designed BA/BE studies provide a solid basis for evaluating the efficacy, safety, and therapeutic equivalence of drugs, thus enhancing patient safety and treatment success [Lourenço et al., 2024]. Therefore, continued support and encouragement for research and methodological advancements in this field are essential.

The Journey of a Drug to Its Target

Bioavailability defines the rate and extent at which a drug enters systemic circulation from the site of administration. More specifically, it is a indicator for the degree to which the drug reaches its target site, where it is expected to act in

its unchanged and active form [Statin J.A., 2021]. Maximizing bioavailability during drug development is critical for ensuring therapeutic efficacy and minimizing adverse effects [Rahban et al., 2023]. Intravenous drug administration is assumed to have 100% bioavailability since the drug is injected directly into systemic circulation, bypassing the absorption phase. However, for other administration routes such as oral, intramuscular, subcutaneous, or transdermal, the drug must traverse absorption barriers [Currie et al., 2018].

The gastrointestinal (GI) system metabolizes drug molecules through first-pass metabolism by enzymes, binding them to the intestinal wall, or metabolizing them in the liver. These losses reduce the amount of drug reaching systemic circulation, thereby decreasing bioavailability [Azman et al., 2022].

Factors Affecting Bioavailability

The factors shaping a drug's BA are complex and multifactorial, ranging from the physicochemical and formulation properties of the drug to the route of administration, patient physiology, and drug-drug interactions [Stielow et al., 2023]. These factors significantly impact the absorption process and, consequently, bioavailability.

Physicochemical properties play a vital role in determining bioavailability. Characteristics such as molecular weight, lipo/hydrophilicity, solubility, crystalline structure, and ionization degree directly influence membrane permeability, dissolution rate, and stability [Stielow et al., 2023]. For instance, a lipophilic drug can readily permeate cell membranes, whereas a drug with poor solubility may experience absorption limitations due to insufficient dissolution in gastrointestinal fluids. Likewise, the crystalline structure of a drug can influence its solubility; amorphous forms generally dissolve faster than crystalline ones [Gigliobianco et al., 2018]. Ionization, which depends on pH, also affects membrane permeability and absorption efficiency [Gaohua et al., 2021].

Formulation characteristics also substantially affect BA. The drug's dosage form (tablet, capsule, solution, suspension, or transdermal patch) influences its dissolution rate, stability, and absorption profile. Excipients such as fillers, binders, solvents, and coating agents can enhance solubility, stabilize the drug in the GI tract, or modify the release profile [Adepu et al., 2021]. For example, the disintegration rate of a tablet or the release behavior of a capsule determines absorption speed.

The route of administration is one of the most significant determinants of BA. The administration route (oral, intravenous, intramuscular, subcutaneous, transdermal, etc.) affects the extent of first-pass metabolism, enzymatic degradation, and the speed of systemic absorption [Markl et al., 2017]. Drugs

taken orally undergo passive diffusion in the GI tract and reach the liver, where first-pass metabolism occurs. This effect can reduce the amount of drug entering systemic circulation and thus lower bioavailability.

Conversely, intravenous administration provides direct access to systemic circulation, resulting in 100% bioavailability. Other routes (intramuscular, subcutaneous, transdermal) exhibit varying absorption rates and BA values [Markl et al.,2017]. Additional physiological factors that may influence BA include age, race, sex, genetics, pathological conditions, dietary factors, pH levels, GI motility, and blood flow to the GI tract. For instance, decreased gastrointestinal blood flow in elderly patients may delay drug absorption [Vinarov et al., 2021]. Genetic variations may alter drug-metabolizing enzyme activity, affecting drug levels in systemic circulation. GI pH and motility also influence drug solubility and absorption.

Drug interactions may significantly alter bioavailability when one drug affects the absorption, metabolism, or elimination of another drug [Bansal et al., 2024]. Some drugs may alter GI pH, affecting the solubility and BA of co-administered medications. Others may inhibit or induce enzymes involved in drug biotransformation, thereby increasing or decreasing plasma concentrations of a drug. These interactions must be carefully considered, as they can alter therapeutic efficacy or increase toxicity risks [Stillhart et al., 2020].

Bioequivalence: Ensuring the Reliability of Generic Drugs

Bioequivalence (BE) refers to pharmaceutical products that, when administered at the same molar dose and under similar conditions, demonstrate comparable bioavailability (in terms of absorption rate and extent). This concept applies when, for example, a solution and a tablet, as two different dosage forms of a drug, exhibit no statistically significant differences in the rate (how fast absorption occurs) and extent (total exposure) of absorption into systemic circulation [Chow SC.,2014]. In this context, bioequivalence indicates that two drugs are metabolized in the body in a comparable manner, thereby providing similar therapeutic outcomes.

BE studies are typically conducted by comparing the pharmacokinetic (PK) profiles of a test drug product (generic) and a reference drug product (innovator) [Chow SC.,2014]. These clinical studies are well-defined scientific investigations aimed at demonstrating that a generic drug exhibits the same clinical effect as the reference drug. This is achieved by analyzing plasma concentration-time data obtained after administering both drug products to volunteers or patients and evaluating key PK parameters.

BE studies are a critical requirement for licensing generic drugs, which are pharmaceutical equivalents of original drugs launched at lower costs after patent protection expires [Voet, M. A. 2020]. For a generic drug to be marketed and considered interchangeable with the reference product, it must be supported by scientifically valid and regulatory agency-approved BE evidence. This ensures that patients using generic drugs experience the same level of safety and therapeutic benefit [Dunne et al., 2015].

BE studies are usually performed under single-dose or multiple-dose conditions in healthy volunteers, and plasma concentration-time data are used to assess specific pharmacokinetic parameters such as area under the curve (AUC), maximum plasma concentration (Cmax), and the time to reach peak concentration (Tmax) [Fuertig et al., 2023]. AUC represents total systemic exposure to the drug over time, while Cmax and Tmax indicate the peak concentration and the time taken to reach it.

Typically, a bioequivalence conclusion is drawn if the ratios of AUC and Cmax values between test and reference products fall within an accepted confidence interval (usually 80%-125%) [Ring et al., 2019]. This range is considered broad enough to prevent clinically significant differences but narrow enough to allow generic drugs to enter the market. Conducting BE studies is a key component in ensuring the efficacy and safety of generic drugs, providing access to lower-cost alternatives without compromising treatment quality [Bate et al., 2016].

The Role of Bioavailability and Bioequivalence in Drug Development

The drug development process is a long and detailed journey where BA and BE principles play a prevalent and critical role at various stages. These principles form the basis of decisions made by the pharmaceutical industry regarding pharmacokinetic characterization, formulation development, dose adjustment, and the licensing of generic drugs [Chow SC.,2014].

Bioavailability is defined as the rate and extent to which an active pharmaceutical ingredient or active moiety is absorbed and becomes available at the site of action via systemic circulation, while bioequivalence compares the BA profiles of different formulations of the same drug under similar conditions [Stielow et al., 2023].

BA studies are conducted during the formulation development phase to compare the pharmacokinetic profiles of various drug formulations. These studies aim to determine how effectively different formulations (e.g., tablets, capsules, solutions, suspensions) of a drug enter systemic circulation [Preeti et al., 2023]. BA data facilitate the selection of an appropriate formulation, increasing the

likelihood of optimizing drug efficacy while minimizing adverse effects. For example, a drug candidate with low BA may be reformulated using solubility-enhancing excipients or an alternative release mechanism to improve its absorption.

BA studies are crucial in dose optimization, which is another key phase of the drug development process. BA-determining studies provide data on the extent of systemic absorption and assist in determining appropriate dosage levels [Stielow et al., 2023]. This helps establish a dosage range that ensures therapeutic efficacy while minimizing the risk of toxicity. BA data, including systemic drug concentration (AUC) and peak plasma concentration (Cmax), are evaluated to establish dose-response relationships [Fuertig et al., 2023, Bhalani et al., 2022]. Drugs with poor BA may require higher doses to achieve therapeutic plasma levels.

Additionally, BA studies contribute to investigating drug interactions during drug development. These studies help assess how a drug's absorption, metabolism, or elimination is altered when co-administered with other drugs [Koziolek et al., 2019]. Drug interactions can significantly affect BA, potentially leading to reduced therapeutic efficacy or increased toxicity risks [Day et al., 2017].

Based on the identification of potential drug interactions through BA studies, appropriate dose adjustments can be made. For instance, if a drug interaction is found to reduce a drug's BA, the dosage may be increased, or the drug may be avoided in combination therapy.

BE studies are a crucial prerequisite for generic drug approval. Generics are lower-cost versions of original drugs whose patents have expired. However, before a generic drug is introduced to the market, BE studies must demonstrate that it is therapeutically equivalent to the reference drug and capable of delivering the same clinical effect [Andrade C., 2015].

BE studies aim to show that the generic and reference drug possess similar bioavailability profiles, indicating that the generic drug will produce the same therapeutic effect as the reference product and will be a safe and effective alternative for patients (Chung Chow, 2014). Additionally, BE testing plays an important role in maintaining the quality and performance of generic drugs, thereby improving access to healthcare by making treatments more affordable for patients [Lavtepatil et al., 2022].

Conclusion

BA and BE are two critical concepts in the drug development process. While BA refers to the rate and extent to which a drug enters systemic circulation, BE determines whether two drug products demonstrate similar BA profiles.

BA optimization plays a key role in drug formulation, dose regimen selection, and the evaluation of drug-drug interactions. Furthermore, comparing BA across different formulations is essential for selecting appropriate treatment strategies. BE studies are especially important in the approval of generic drugs, as they assess whether generics provide equivalent therapeutic effects compared to reference drugs. BE ensures that generic drugs serve as both reliable and cost-effective therapeutic alternatives.

Strategically applying BA and BE at every stage of a drug's lifecycle enhances the overall development plan and improves product outcomes. A sound understanding of these concepts helps in developing better, safer, and more affordable drugs. We emphasize the significance of BA and BE studies for pharmaceutical companies, regulatory authorities, and healthcare professionals dedicated to patient health. A deeper understanding of these concepts will also facilitate the advancement of personalized medicine approaches.

References

Stielow M, Witczyńska A, Kubryń N, Fijałkowski Ł, Nowaczyk J, Nowaczyk A. The Bioavailability of Drugs—The Current State of Knowledge. *Molecules*. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

Chow SC. Bioavailability and bioequivalence in drug development. *Wiley Interdiscip Rev Comput Stat*. 2014;6:304–12.

KURT, A. A., & Ibrahim, B. (2024). Preparation of New Generation Natural Repellent Formulations From Essential Oils: From Basic Research to Technological Development. *Journal of Cosmetic Science*, 75(4).

Pawar G, Wu F, Zhao L, Fang L, Burckart GJ, Feng K, et al. Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products. *AAPS Journal*. 2021;23.

Patel D, Desai D, Mehta FA, Professor A. A Review on the Importance of In-vitro Bioavailability and Bioequivalence Studies. *Journal of Pharmacology, Toxicology and Therapeutics* [Internet]. 2020; Available from: <https://www.researchgate.net/publication/346476767>

Zuo X, Zhao X, Shi J, Zhang T. Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions. *BMC Pharmacol Toxicol*. 2024;25.

Lynggaard H, McKendrick S, Baird M, Kerwash E, Lanius V, Lasch F, et al. Applying the estimand framework to clinical pharmacology trials with a case study in bioequivalence. *Br J Clin Pharmacol*. John Wiley and Sons Inc; 2024.

Lourenço D, Miranda M, Sousa JJ, Vitorino C. Therapeutic-driven framework for bioequivalence assessment of complex topical generic drug products. *Int J Pharm*. Elsevier B.V.; 2024.

Statin J. A brief Note on Bioavailability and Its Significance. *J Bioequiv Availab*. 2021.

Rahban M, Ahmad F, Piatyszek MA, Haertlé T, Saso L, Saboury AA. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. *RSC Adv*. Royal Society of Chemistry; 2023. p. 35947–63.

Currie GM. Pharmacology, part 2: Introduction to pharmacokinetics. *J Nucl Med Technol*. 2018;46:221–30.

Azman M, Sabri AH, Anjani QK, Mustaffa MF, Hamid KA. Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. *Pharmaceuticals*. MDPI; 2022.

Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of poorly soluble drugs: Drug bioavailability and physicochemical stability. *Pharmaceutics*. MDPI AG; 2018.

Gaohua L, Miao X, Dou L. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. *Expert Opin Drug Metab Toxicol*. Taylor and Francis Ltd.; 2021. p. 1103–24.

Adepu S, Ramakrishna S. Controlled drug delivery systems: Current status and future directions. *Molecules*. MDPI; 2021.

Markl D, Zeitler JA. A Review of Disintegration Mechanisms and Measurement Techniques. *Pharm Res*. Springer New York LLC; 2017. p. 890–917.

Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, et al. Impact of gastrointestinal physiology on drug absorption in special populations—An UNGAP review. *European Journal of Pharmaceutical Sciences*. 2020;147.

Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. *European Journal of Pharmaceutical Sciences*. 2021;162.

Bansal N, Momin S, Bansal R, Venkata SKRG, Ruser L, Yusuf K. Pharmacokinetics of drugs: newborn perspective. *Pediatric Medicine*. AME Publishing Company; 2024.

Voet, M. A. (2020). The generic challenge: understanding patents, FDA and pharmaceutical life-cycle management. BrownWalker Press.

Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. *BMC Med*. 2015;13.

Fuertig R, Goettel M, Herich L, Hoefler J, Wiebe ST, Sharma V. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies. *CNS Drugs*. 2023;37:1081–97.

Ring A, Lang B, Kazaroho C, Labes D, Schall R, Schütz H. Sample size determination in bioequivalence studies using statistical assurance. *Br J Clin Pharmacol*. 2019;85:2369–77.

Bate R, Mathur A, Lever HM, Thakur D, Graedon J, Cooperman T, et al. Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDA. *Trends Pharmacol Sci*. Elsevier Ltd; 2016. p. 184–91.

Preeti, Sambhakar S, Saharan R, Narwal S, Malik R, Gahlot V, et al. Exploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review. *Saudi Pharmaceutical Journal*. Elsevier B.V.; 2023.

Bhalani D V., Nutan B, Kumar A, Singh Chandel AK. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. *Biomedicines*. MDPI; 2022.

Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, et al. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. *European Journal of Pharmaceutical Sciences*. 2019;134:31–59.

Day RO, Snowden L, McLachlan AJ. Life-threatening drug interactions: what the physician needs to know. *Intern Med J*. 2017;47:501–12.

Andrade C. Bioequivalence of generic drugs: A simple explanation for a US Food and Drug Administration requirement. *Journal of Clinical Psychiatry*. Physicians Postgraduate Press Inc.; 2015. p. e742–4.

Lavtepatil S, Ghosh S. Improving access to medicines by popularising generics: a study of ‘India’s People’s Medicine’ scheme in two districts of Maharashtra. *BMC Health Serv Res*. 2022;22.

Chapter 6

Biopharmaceutical Classification System (BCS): Basic Principles, Application to Cancer Drugs, and the Role of Microorganisms in BCS Assessment

**Ahmet Arif KURT¹, Buse ZEREN²,
Duygu TÜRKMEN³, Bashar IBRAHIM⁴**

Abstract

The drug-classifying model is known as the Biopharmaceutics Classification System (BCS) has become an essential tool in pharmaceutical sciences, influencing drug development, formulations strategies, and the regulatory approval pathway. The role of BCS is discussed in this chapter, which highlights its core principles and features, emphasizing the biopharmaceutical evaluation of anticancer drugs. Solubility and permeability are the critical parameters that affect the fate of a drug, and in this guide, we will explore these two critical parameters and how they can affect absorption and bioavailability. Additionally, we discuss the BCS classification of commonly used anticancer agents, emphasizing the formulation challenges associated with each class and the innovative strategies employed to overcome these hurdles. Special attention is given to the potential for biowaivers based on BCS principles in the context of anticancer drug development. Finally, in this review, the evaluation of cancer drugs according to the BCS system and the possible effects of microorganisms on this evaluation will be examined in detail.

Keywords: Biopharmaceutical Classification System, Solubility, Drug Absorption, Cancer Drugs, Formulation Development

¹ Süleyman Demirel University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Isparta, Türkiye; ahmetkurt@sdu.edu.tr, ORCID No: 0000-0002-3490-0192

² bussezeren@gmail.com ORCID No: 0009-0002-7052-4769

³ duyguturkmen6420@gmail.com ORCID No: 0009-0008-5395-1236

⁴ Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Süleyman Demirel University, Isparta 23000 Türkiye. basharibrahim@sdu.edu.tr ORCID No: 0000-0003-3086-0995

Introduction

The Biopharmaceutical Classification System (BCS), emerges, more recently, as a rational avenue in pharmaceutical sciences, which offers awarding to pharmaceutical products by aiding the drug development processes and serving as a fundamental tool to bioequivalence study. BCS is the basis for many drug formulations available in the market and predicts the fate of active pharmaceutical ingredients (APIs) in the gastrointestinal tract which enables the optimization of drug formulations (Widmer et al. The foundation knowledge of BCS principles in this regard is extremely important for a successful and efficient drug development process (Samineni, 2022; Shukla, 2017).

The major drug absorption barrier facing a drug (administered orally) is the solubility and permeability of a drug to reach the systemic circulation. The solubility of a drug is the ability of that drug to dissolve in gastrointestinal fluids while permeability describes the ability of a drug to pass through gastrointestinal epithelial cells and enter into the bloodstream. Low-solubility or low permeability drugs can have problems with oral bioavailability, which can affect their therapeutic efficacy. Hence, improving solubility and permeability are the key properties during the design development of a pharmaceutical product (Stielow, 2023).

In addition, BCS has also been involved in drug development formulation optimization and regulatory approval stages. During the drug development process, BCS classification can guide formulation strategies and predict bioavailability issues. During formulation optimization, drug solubility and permeability can be increased using approaches appropriate for BCS class I. During the regulatory approval stage, BCS-based biodegradation studies that exclude *in vivo* bioequivalence studies can accelerate the process, which can reduce development costs and costs by reducing *in vivo* bioequivalence studies under certain conditions (Dhake, 2024).

Cancer drugs are a group of drugs that require more special attention due to their properties and the difficulties they can give to the treatment. Many of them can cause low solubility, off-target toxicity, and effects; many of them can develop a series of mechanisms against drug resistance of cancer cells like islanders. This means that the development and formulation of cancer drugs for the treatment of the disease requires the integration of BCS principles and the use of innovative drug delivery systems (Khan, 2024).

The main purpose of this section is to examine in detail the basic principles of the Biopharmaceutical Classification System (BCS) and its applications in drug development processes. It also presents current approaches and future perspectives in this field by addressing the pharmaceutical properties of cancer

drugs and how they are evaluated according to the BCS system. This section aims to be a comprehensive resource for researchers, students, and industry professionals working in the field of pharmaceutical sciences.

2. Determination of Solubility and Permeability

To correctly classify an active pharmaceutical ingredient (API) under the BCS, it is essential to determine its solubility and permeability properties using reliable and reproducible methods. These determination processes allow for critical decisions during drug development and formulation and play an important role in predicting the oral bioavailability of the drug (Samineni, 2022).

2.1. Solubility Test Methods

Solubility is defined as the ability of a substance to dissolve in a particular solvent at a particular temperature and is a critical parameter for drug formulations. Solubility tests are performed by various methods to understand the dissolution behavior of the API in different physiological conditions (Borgaonkar, 2024).

2.1.1. pH Dependent Solubility

Drugs solubility is strongly dependent on pH, which is also different in each part of the gastrointestinal tract. Weakly acidic or basic drugs have pH-dependent solubility. Solubility tests are thus carried out at different physiological pH values, including the stomach (pH 1.2–3.0), duodenum (pH 6.0–6.5) and ileum (pH 7.0–7.5). Generally, these tests are carried out in buffer solutions, and the dissolution of the API is traced until equilibrium solubility is achieved. Feel free to translate in your own words or get inspired from the passage of your selection in case you donot have data passage to paraphrase as in this case we should give data passage to paragraphs as follow (Rangaraj, 2024).

2.1.2. Solubility in Different Solvents

The solubility of drugs is also affected by factors such as the polarity, ionic strength, and presence of the solvent. Therefore, solubility tests are performed in different solvents such as water, buffer solutions, organic solvents, and physiological fluids. Tests can also be performed to evaluate the effect of surfactants that can form micelles (e.g. sodium lauryl sulfate) on solubility. These tests are important to understand the interaction of the API with different formulation components and to determine suitable solvent systems (Bhalani, 2022).

2.1.3. Equilibrium Resolution

Equilibrium solubility is the highest level of drug that can be dissolved at a specific temperature and solvent when the dissolution rate and the precipitation rate are in balance. This value can also be used to assess the drug's solubility potential. Equilibrium solubility is typically found by adding an excess of API in solvent and sampling in intervals to measure the concentration of the dissolved drug (Avdeef, 2016).

3.1.4. Kinetic Resolution

Kinetic solubility is the rate at which a drug dissolves in solute. This parameter is particularly critical for poorly soluble drugs, as the dissolution rate controls the absorption of the drug from the GI tract. Spectrophotometric or HPLC methods that can monitor the dissolution process in real-time are typically used to conduct kinetic solubility tests (Zarghampour, 2024).

2.2. Permeability Test Methods

Permeability refers to the ability of a drug to pass through gastrointestinal epithelial cells and reach the bloodstream. Permeability tests are performed using different methods, including *in vitro*, *in situ*, and *in vivo* (Fedi, 2021).

2.2.1. In Vitro Cell Culture Models

2.2.1.1. Caco-2 Cells

Caco-2 cells are a human colorectal adenocarcinoma cell line that display characteristics of small intestinal epithelial cells. These cells are interconnected by tight junctions, creating a monocrystalline layer and simulating the gastrointestinal barrier. Drug permeability is assessed by calculating the amount of drug transported from the apical to the basolateral area (or vice versa). Introduction: Caco-2 cell model is a well known method that being used as *in vitro* static parameters for drug permeability (Jorgensen, 2025).

2.2.1.2. Parallel Artificial Membrane Permeability Assay

The Parallel Artificial Membrane Permeability Assay (PAMPA) is the *in-vitro* system for the assay of drug permeability using an artificial membrane system. In this approach, drug molecules are transferred from one to another lipid-based membrane compartment, which can also be an organ *in vivo*. The concentrations of the drug in each compartment are measured, which determines permeability. Since PAMPA is a fast and economical method, it is appropriate to be adapted for high-throughput screening (Teixeira, 2020).

2.2.1.3. MDCK (Madin-Darby Canine Kidney) Cells

MDCK cells are a cell line derived from canine kidney cells and have polarized epithelial cell properties. MDCK cells can be used to assess drug permeability, but are less representative of the human gastrointestinal barrier compared to Caco-2 cells (Ebert, 2024).

2.2.1.4. In Situ Intestinal Perfusion Studies

In situ Intestinal perfusion studies are performed by perfusing a segment of the small intestine of a conscious (usually rat) animal. The drug is mixed into the perfusion fluid and permeability is then obtained by measuring the transfer rate through intestinal wall. This approach offers a more in vivo-like environment versus in vitro methods and allows assessment of drug metabolism, drug transport, and gut-microbiome interactions (Kim, 2018).

2.2.1.5. In Vivo Pharmacokinetic Studies

In vivo pharmacokinetic studies are performed to evaluate the behavior of a drug in an animal or human body. The drug is usually administered orally, and blood samples are taken at specific time intervals to measure drug concentrations. Pharmacokinetic parameters (e.g., rate of absorption, bioavailability) provide information about the permeability of the drug. In vivo studies are essential for confirming in vitro and situ data (Stielow, 2023).

2.3. Critical Parameters and Threshold Values Used in BCS Classification

In BCS classification, solubility and permeability are the basic parameters and are evaluated with threshold values that determine which class the drugs belong to. For high solubility, the highest therapeutic dose should be dissolved in a volume of less than 250 mL at pH 1.2-6.8, while for high permeability, at least 85% of the oral dose is expected to be absorbed or to show permeability higher than 1×10^{-6} cm/s in Caco-2 cells. However, since these threshold values can be affected by factors such as polymorphism, salt formation, particle size, recipients, drug metabolism, and transport mechanisms, BCS classification requires careful evaluation and expert opinion (Chavda, 2010; Arrunátegui, 2015)

2.3.1. Solubility

To be classified as “highly soluble” under the BCS, the highest therapeutic dose of an active pharmaceutical ingredient (API) must be capable of dissolving in an aqueous solution of 250 mL or less at 37°C and in the physiologically relevant pH range (pH 1.2 to pH 6.8). This criterion is the volume of contents that a patient would have on an empty stomach and thus shows that the drug can

dissolve, if necessary in the gastrointestinal tract, and thus it is in a state that will render it absorbable, which prevents solubility from being a speed bump in the road of oral bioavailability (Miranda, 2024).

2.3.2. Permeability

For a drug to be considered "highly permeable", at least 85% of the oral dose must be absorbed in humans or permeable to Caco-2 cells above a certain threshold (usually 1×10^{-6} cm/s) (Kus, 2023).

3. Drugs and Their Properties According to BCS Classes

The Biopharmaceutical Classification System (BCS) provides important guidance in the drug development process by classifying the absorption characteristics of drugs when administered orally according to their solubility and permeability parameters. This classification plays a critical role in determining drug formulation strategies, guiding bioequivalence studies, and communicating with regulatory authorities. Divided into four basic classes, the BCS highlights the different pharmaceutical properties of drugs and potential bioavailability issues (Kus, 2023).

Class 3.1 Drugs: High Solubility, High Permeability

BCS Class I drugs contain active pharmaceutical ingredients (APIs) that are both highly soluble and highly permeable. High solubility means that the drug is soluble in sufficient amounts over a wide pH range, while high permeability means that it can easily pass through gastrointestinal epithelial cells. These properties generally result in drugs that are well absorbed and have high oral bioavailability (Samineni, 2022).

Class I drugs generally dissolve rapidly and completely in the gastrointestinal tract, which ensures that the drug is available in a form suitable for absorption. Due to their high permeability, dissolved drug molecules easily pass through epithelial cells and reach the bloodstream. Therefore, formulation development processes for Class I drugs are generally simpler and do not require complex drug delivery systems (Panwar, 2021).

Class I drugs with bioequivalence problems are rare because the drug is released in the gastrointestinal tract and absorbed quickly, resulting in consistent bioavailability for all formulations. But in some cases it can differ, either through the effects of recipients or formulation techniques. Hence, it is necessary to exercise caution during formulation development and conduct appropriate bioequivalence studies even for Class I drugs (Koziolek 2024).

3.2. Class II Drugs: Low Solubility, High Permeability

BCS Class II drugs include APIs that have low solubility but high permeability. The absorption of these drugs is limited by their solubility. That is, the drug is not sufficiently soluble in the gastrointestinal tract, so despite its ability to pass through epithelial cells, it is not absorbed in sufficient amounts. This can lead to low and variable oral bioavailability (Lodhi, 2021).

Formulation of Class II drugs focuses on strategies to increase solubility. These strategies include:

3.2.1. Solid Dispersions

Formulations were obtained by dispersing the API in a water-soluble carrier (e.g., polyvinylpyrrolidone, polyethylene glycol). Solid dispersions can increase solubility by increasing the effective surface area of the API and improving the rate of dissolution (Chunduru, 2024).

3.2.2. Nanocrystals

These are formulations obtained by reducing the API to NATO sizes. Monocrystals can increase solubility thanks to their high surface area and dissolution rate (Yanamadala, 2025).

3.2.3. Amorf Formülasyonlar

Amorphous formulations are solid-state pharmaceutical forms obtained by the disruption of the crystalline structure and the molecules are arranged irregularly; this structural difference causes them to have a higher Gibbs free energy compared to crystalline forms, making them less stable thermodynamically, but generally exhibiting higher solubility and dissolution rates. While the regular arrangement of molecules in crystalline structures requires more energy in the dissolution process, the irregular arrangement of molecules in amorphous structures allows them to interact more easily with solvent molecules and therefore dissolve faster; this is considered a critical strategy to increase the bioavailability of drugs, especially those with low solubility. However, the high-energy nature of amorphous formulations can make them prone to crystallization over time, which can lead to reduced solubility and bioavailability; therefore, a common approach is to form dispersions or complexes using polymers, surfactants, or other excipients to increase the stability of amorphous formulations (Tambe, 2022; Newman, 2017).

3.2.4. Salt Creation

Using a salt form of the API can increase solubility. Salting is a common solubility-enhancing strategy, especially for drugs that are weakly acidic or basic (Gupta, 2018).

3.2.5. Surface Active Substances (Surfactants)

The use of surfactants can increase the solubility of the API by forming micelles (Lange, 2025).

Formulation development for Class II drugs requires extensive in vitro and in vivo studies to evaluate the efficacy of strategies to increase solubility. Additionally, formulation stability and long-term solubility performance must also be considered (Lange, 2025).

3.3. Class III Drugs: High Solubility, Low Permeability

BCS class III drugs are APIs with high solubility but low permeability. Permeability limits the absorption of these drugs. That is, while the drug is soluble enough in the gastrointestinal tract, it is not absorbed in adequate amounts due to limited permeability across epithelial cells. Oral bioavailability is low and variable (Truzzi, 2021).

The permeability of Class III drugs can be affected by several factors:

3.3.1. Molecular Size and Shape

Molecular size and shape are the main factors affecting the passage of drugs through transcellular and paracellular pathways. Large molecular weight and bulky drugs may have difficulty passing through pores in cell membranes due to strict hindrance, while complex and irregular shapes may also make interaction with membrane proteins difficult and prevent passage by passive diffusion, making the paracellular passage route, which is limited due to tight junctions in gastrointestinal epithelial cells, even more important, as this route is generally not a suitable alternative for large and polar molecules (Pawar, 2022; Khalil, 2024).

3.3.2. Polarity and Ionization

Highly polar -or ionized-form drugs encounter considerable difficulty passing through lipid bilayer cell membranes; this is because the solubility of polar and charged molecules in the membrane structure based on hydrophobic interactions is low, and these molecules consequently have to overcome high energy barriers to go through the hydrophobic environment in the cell membrane. Drug molecules may be partially or fully ionized depending on pH, which may alter drug solubility and/or permeability since weak acids are protonated to a less ionized

(more keratinous) form in low pH while weak bases are protonated to a less ionized (more keratinous) form in a high pH, and in both those cases making the drug more lipophilic which in turn facilitate membrane permeation (refer to this under the Formulation and Stability discussion). Yet, lipophilic tendency also hinders drug translocation through aqueous membranes, hence, a lipophilic-hydrophilic balance is paramount for effective membrane translocation (Mehta, 2023; Bennion, 2017).

3.3.3. Carrier-Mediated Transport Mechanisms

Some drugs are transported by carrier proteins found in epithelial cells. The activity of these transporters can affect drug permeability (Wanat, 2020).

3.3.4. Paracellular Transport

Some drugs can pass through the spaces between epithelial cells (through tight junctions). However, this route is generally limited to small molecules and water.

Formulation of Class III drugs focuses on strategies to increase permeability. These strategies include (Wu, 2024).

3.3.5. Increasing Carrier-Mediated Transport

Enhancing carrier mediated transport strategy is an important approach to enhance the bioavailability of drugs with low permeability (BCS Class III and IV) that can modulate the activity of carrier proteins that are responsible for the movement of endogenous substrates or drugs across cell membranes (Bara, 2025). Although gene therapy or pharmacological agents that alter the activity at the level of transcription factors could, in principle, upregulate carrier expression, in general, lower cost solutions could be to use recipients that directly affect the activity of carrier proteins by binding to these proteins and inducing conformational change that increase drug binding or the rate of drug transport, for example. Another method involves the application of competitive inhibitors with affinity to carrier proteins, preventing the transport of endogenous substrates and leading to the enhanced transport of drugs, though this approach needs to be applied with caution considering possible side effects and drug interactions. Carrier-mediated transport has been very successful, but various parameters like the specificity of the carrier protein, the binding affinity of the drug to the carrier, the efficiency of the recipient and toxicity should be optimized in great detail (Pudlarz, 2018; Diaz, Dinamarca, 2022).

3.3.6. Temporarily Opening Tight Links

The strategy of temporarily opening tight junctions is an approach that aims to increase the absorption of low-permeability drugs (BCS Class III and IV) using the paracellular transport pathway; tight junctions are complex protein complexes located between epithelial and endothelial cells and control permeability by closing the intercellular spaces. Temporary openings of these junctions can increase drug absorption by allowing larger molecules and polar substances to pass through the intercellular spaces. Calcium creators (e.g., EDTA) can disrupt the integrity of tight junction proteins by binding calcium, while some substances, such as acylcarnitines, can increase the permeability of the junctions by affecting the signaling pathways involved in the regulation of tight junction proteins. However, the strategy of opening tight junctions has the potential to compromise the integrity of the epithelial barrier, and requires careful optimization to minimize side effects such as toxicity and inflammation; in addition, the effectiveness of this approach depends on factors such as the concentration of the substance used, the duration of application, drug properties, and physiological conditions (Brunner, 2021; Baral, 2025).

3.3.7. Peptide or Protein Based Transport Systems

Peptide or protein-based delivery systems are a sophisticated approach to enhance the bioavailability of low-permeability drugs (BCS Class III and IV) by facilitating the transport of drugs into epithelial cells. These systems contain peptide or protein ligands that can bind to specific receptors or carrier proteins on the epithelial cell surface, thereby promoting drug uptake (endocytosis). For example, transferring protein binding to the transferring receptor or folic acid binding to the folate receptor are commonly used ligands for targeting drug-loaded nanoparticles or liposomes to epithelial cells, where they facilitate drug uptake via receptor-mediated endocytosis. Alternatively, some peptides may function as cell-penetrating peptides (CPPs), which facilitate direct passage through epithelial cell membranes; these peptides may contain positively charged amino acids or hydrophobic residues and interact with membranes, thereby facilitating drug uptake into the cell. Design of peptide or protein-based delivery systems requires careful optimization of factors such as ligand affinity for the receptor, stability of the system, drug loading capacity, release kinetics, and toxicity potential. Formulation development of Class III drugs requires extensive *in vitro* and *in vivo* studies to evaluate the efficacy of strategies to increase permeation. Additionally, the toxicity potential and long-term effects of these strategies must be considered (Brayden, 2020; Neaz, 2024).

3.4. Class IV Drugs: Low Solubility, Low Permeability

BCS Class IV drugs include APIs with both low solubility and low permeability. The absorption of these drugs is limited by both solubility and permeability. That is, the drug is not sufficiently soluble in the gastrointestinal tract, and even if it is soluble, it is not absorbed in sufficient amounts due to its limited ability to pass through epithelial cells. This leads to the lowest and most variable oral bioavailability (Samineni, 2022). The formulation of Class IV drugs presents the greatest challenges and often requires the use of innovative drug delivery systems. These strategies include (Ezike, 2023).

3.4.1. Nanoparticles

Formulating the API into hand-sized particles can increase solubility and permeability. Nanoparticles can be more easily taken up by cells and can remain in the gastrointestinal tract for longer periods (Yusuf, 2023).

3.4.2. Liposomes

Encapsulation of API in lipid-based vesicles can increase solubility and permeability. Liposomes can fuse with cell membranes, facilitating the transport of the drug into the cell (Giordani, 2023).

3.4.3. Micelles

Dissolving the API in micelles formed with surfactants can increase solubility. Micelles can provide better distribution of the API in the gastrointestinal tract (Xie, 2024).

3.4.4. Targeted Drug Delivery Systems

Transport systems that enable specific targeting of the API to tumor cells or diseased tissues can reduce systemic toxicity and increase therapeutic efficacy (Ezike, 2023).

4. Applications of BCS in Drug Development

The Biopharmaceutical Classification System (BCS) serves as a valuable guide at various stages of the drug development process, offering a wide range of applications from determining formulation development strategies to designing bioequivalence studies, assessing the potential of biodegradable studies to developing controlled release systems and implementing new drug delivery systems (Samineni, 2022).

4.1. Determination of Formulation Development Strategies

BCS allows rational determination of formulation development strategies by classifying drugs according to their solubility and permeability properties. For example, formulation techniques aimed at increasing solubility (e.g., solid dispersions, monocrystals, amorphous formulations, salt formation) are prioritized for drugs with low solubility (BCS Class II and IV), while strategies aimed at increasing permeability (e.g., enhancing carrier-mediated transport, transient opening of tight junctions, peptide or protein-based transport systems) are prioritized for drugs with low permeability (BCS Class III and IV). BCS classification helps formulation scientists to identify the main limiting factors of the drug molecule and to select the most appropriate formulation approach to overcome these factors. BCS also guides the selection of formulation components, allowing to avoid recipients that may negatively affect solubility or permeability (Samineni, 2022; Ku and Dulin, 2010).

4.2. Design and Interpretation of Bio Equivalence Studies

Molecular size and solubility are critical for the design and interpretation of bioequivalence studies. Bioequivalence studies are conducted *in vivo* to demonstrate that generic drugs have the same bioavailability as reference drugs (Arrunategui, 2015). BCS has been used to predict the bioavailability effect of formulation changes in drugs about solubility and permeability properties. For instance, if the drug is highly soluble and has high permeability (BCS Class I), no significant effect on bioavailability is expected with changes in formulation, whereas the effects would be significant for drugs with low solubility or low permeability (BCS Class II, III, and IV). Thus, BCS classification should be considered in the design (e.g., sample size, dose, route of administration) and interpretation of bioequivalence studies, thus preventing unnecessary *in vivo* studies and lowering drug development costs (Dahke, 2024).

4.3. Potential of Biowaiver Studies

BCS is an important tool to evaluate the potential of biodelayed studies that obviate the need for *in vivo* bioequivalence studies under certain conditions. Biodelayed studies can be applied to drugs that demonstrate a good correlation between *in vitro* dissolution tests and *in vivo* bioavailability. Drugs with high solubility and high permeability (BCS Class I) are generally suitable candidates for biodelayed studies because their dissolution is rapid and complete in the gastrointestinal tract and formulation changes are not expected to have a significant impact on bioavailability. However, the feasibility of delayed studies depends on the characteristics of the drug, the type of formulation, and the quality

of in vitro dissolution tests. Regulatory authorities (e.g., FDA, EMA) have published specific criteria and guidelines for biodelayed studies, and compliance with these criteria is critical for the acceptability of biodelayed studies (Arrunátegui, 2015; Miranda, 2021).

4.4. Development of Controlled Release Systems

BCS provides valuable information in the development of controlled release systems. Controlled release systems are formulations that aim to increase therapeutic efficacy and reduce side effects by releasing a drug at a specific rate and for a specific duration. BCS classification helps predict which drugs may benefit most from controlled release systems. For example, for drugs with low solubility (BCS Class II and IV), controlled-release systems can increase bioavailability by prolonging drug dissolution and absorption, while for drugs with high solubility and low permeability (BCS Class III), controlled-release systems can increase absorption by allowing the drug to persist in the gastrointestinal tract for a longer time. The design of controlled release systems is determined by the solubility and permeability properties of the drug, the desired release profile, and the route of administration (Adepu, 2021; Samineni, 2022).

4.5. Application of New Drug Delivery Systems (For example, Nanotechnology-Based Systems)

BCS guides the implementation of novel drug delivery systems (e.g., nanotechnology-based systems). Nanotechnology-based systems involve the formulation of drugs into canonized particles, which can improve the therapeutic efficacy of drugs by increasing solubility, permeability, stability, and targeting. The BCS classification helps predict which drugs may benefit most from nanotechnology-based systems. For example, for drugs with low solubility and low permeability (BCS Class IV), nanotechnology-based systems can significantly improve bioavailability by simultaneously increasing drug dissolution, absorption, and targeting. The design of nanotechnology-based systems is determined by the properties of the drug, the targeted tissue or cell, and the desired release profile. However, the toxicity potential, stability, and manufacturing scalability of nanotechnology-based systems must also be considered (Adepu, 2021; Samineni, 2022).

5. Regulatory Importance of BCS

In addition to facilitating drug development processes, BCS is increasingly being accepted by regulatory authorities and plays an important role in drug licensing processes. BCS has a wide range of regulatory importance, from ensuring regulatory acceptance of biodegraded studies to guiding generic drug

development processes, from increasing the impact of drug licensing processes to international harmonization efforts (Cook, 2010).

5.1. Regulatory Acceptance of a Deferred Study

BCS plays a critical role in ensuring regulatory acceptance of biowaiver studies, which reduces the need for in vivo bioequivalence studies and lowers drug development costs. Regulatory authorities (e.g., FDA, EMA) state that biowaiver studies are acceptable under certain conditions for drugs that demonstrate a good correlation between in vitro dissolution tests and in vivo bioavailability. BCS Class I drugs are generally considered suitable candidates for biowaiver studies, while the feasibility of biowaiver studies for BCS Class II, III, and IV drugs depends on the characteristics of the drug, the type of formulation, and the quality of the in vitro dissolution tests. Regulatory acceptance of biowaiver studies requires accurate determination of the drug's solubility and permeation properties, use of appropriate in vitro dissolution tests, and rigorous evaluation of the data obtained (Metry and Polli, 2022).

5.2. The Role of GIS in Generic Drug Development Processes

BCS plays an important role in generic drug development processes, allowing to reduce the number of in vivo studies required to prove bioequivalence with reference drugs and to accelerate the introduction of generic drugs to the market. Using the BCS classification, generic drug companies can predict the potential effects of formulation changes on bioavailability and design the necessary bioequivalence studies accordingly. For example, for BCS Class I drugs, formulation changes are not expected to have a significant impact on bioavailability, while for BCS Class II, III, and IV drugs, formulation changes may have a significant impact on bioequivalence and may require more extensive in vivo studies. BCS helps generic drug companies use resources more efficiently and optimize drug development processes (Cook, 2010; Samineni, 2022).

5.3. Impact of BCS on Drug Licensing Processes

BCS is also increasingly influential in drug registration processes, playing an important role in the evaluation of solubility, permeability and bioavailability properties of drugs by regulatory authorities. In new drug applications (NDA), pharmaceutical companies can support the formulation strategy and bioavailability of the drug by submitting data on BCS classification. Regulatory authorities can evaluate the appropriateness of the formulation, the design of bioequivalence studies and the potential of biodegraded studies by evaluating BCS data. BCS facilitates patients' access to safe and effective drugs by making

drug registration processes more transparent, rational, and scientifically based (Ghadi and Dand, 2017).

5.4. International Harmonization Efforts

A BCS is a powerful tool to foster the international harmonization of drug development and regulatory processes. Applying the BCS principles, various regulator authorities around the world are making efforts towards harmonizing the data requirements for marketing authorization of the drug. BCS in ICH guidelines, published by the International Council for Harmonization (ICH), help to reduce regulatory differences between member countries and aid in the drug development process. The BCS, is also an international harmonized document, which helps to facilitate the pharmaceutical companies in a global market, however guarantees that patients from different countries have the same quality drugs (Aceituno, 2021).

6. BCS's Limits and Future Perspectives

While the BCS has transformed drug development and regulatory processes, there are limitations and the need for update with the evolving science and technology. BCS is perhaps sufficient for some drugs, but not others, requiring continuous update with emerging technologies; there are progressions concerning establishment of new in vitro and in silico models, and BCS's involvement in personalized drug treatment approaches are all key topics for the future of BCS (Miranda, 2021).

6.1. BCS may be inadequate for some drugs (e.g., biological drugs, prodrugs)

BCS was developed primarily for small molecule, synthetic drugs and may be inadequate for some drug categories. Biological drugs (e.g. proteins, antibodies, peptides) may not fully comply with the BCS principles due to their large molecular weight, complex structure, and different absorption mechanisms. In addition, prodrugs (drugs that are metabolized in the body to become active) may cause problems in BCS classification because the solubility and permeability properties of the prodrug itself may differ from the properties of the active metabolite, making it difficult to accurately predict bioavailability. Therefore, modified versions of BCS or alternative classification systems need to be developed for biologics and prodrugs (Chavda, 2010).

6.2. The Need to Update BCS with Emerging Technologies

Drug development technologies are constantly evolving and new formulation strategies and drug delivery systems are emerging. Therefore, BCS needs to be

updated to reflect current technologies. For example, nanotechnology-based systems can significantly improve bioavailability by increasing the solubility, permeability, and targeting of drugs; however, the current version of BCS cannot fully evaluate the effects of nanotechnology-based systems. In addition, the development of new in vitro and silico models allows for more accurate prediction of drug solubility and permeability properties, and integrating these models into BCS can increase the accuracy and applicability of the system (Elumalai, 2024).

6.3. Development of New In Vitro and In Silico Models

BCS relies on n vitro and in silico models to predict the solubility and permeability properties of drugs. While traditional in vitro models (Caco-2 cells, PAMPA, etc.) are useful for determining passive drug permeation through simplified membranes, they cannot recreate biologically relevant processes (active transport, metabolism, efflux, etc.). Thus, by utilizing advanced in vitro models (3D Cell Cultures, Microfluidic Devices, Gut-Chip Systems, etc.), more reliable drug absorption prediction may be achieved. These methods can be applied at the molecular level to determine solubility and permeability properties of drugs (in silico models, i.e. ADME prediction if computational approaches of the molecular dynamics simulations), thus helping to reduce the time and costs of in-vitro studies. In silico models are only as accurate as the algorithms used to generate them and the datasets they are trained on (O'Shea, 2022).

6.4. The Role of CBS in Individualized Medication Approaches

Personalized medicine involves tailoring drug therapy to each patient's genetic profile, lifestyle, and environmental factors. BCS can play an important role in individualized drug therapy approaches because the solubility and permeability properties of drugs may vary depending on the patient's physiological status, genetic variations, and drug interactions. For example, the gastrointestinal pH or gut microbiota of some patients may affect the solubility or absorption of drugs. Therefore, BCS classification can guide the adjustment of drug dosage or formulation according to the patient's characteristics. In addition, pharmacogenomic tests can identify genetic variations that affect drug metabolism, and this information can be used in drug selection and dose adjustment. The widespread use of individualized drug therapy approaches will lead to the BCS gaining more importance and the development of the system to take into account patient-specific factors (Su, 2024).

7. Case Studies

To better understand the practical applications and implications of the Biopharmaceutical Classification System (BCS) in drug development, examples of drug development processes in different BCS classes, examples of success and failure of biopharmaceutical studies, and examples of how formulation strategies are determined according to the BCS classification are presented (Samineni, 2022).

7.1. Examples of Development Processes for Drugs in Different BCS Classes

BCS Class I: Metoprolol Tartrate: The Metoprolol tartrate is a high solubility-high permeability (BCS Class I) β -blocker 6. As metoprolol tartrate does not have solubility and permeability problems, formulation studies were generally performed by simple and traditional methods in the development process. Different formulations of metoprolol tartrate have been shown to be bioequivalent in bioequivalence studies, enabling the development of generic drugs. Metoprolol tartrate colocated biodegraded studies are widely accepted, which reduces the number of in vivo studies.

BCS Class II: Ketoconazole: Ketoconazole is an antifungal drug with low solubility but high permeability. Formulation strategies to increase solubility (e.g., solid dispersions, and micronation) have played an important role in the development of ketoconazole. The bioavailability of ketoconazole can vary significantly depending on the type of formulation and particle size, and therefore bioequivalence studies should be carefully designed. Biodegradation studies are more complex for ketoconazole, as the rate of dissolution can significantly affect bioavailability, and in this case, in vitro dissolution tests must correlate well with in vivo data.

BCS Sınıf III: Simetidin: Cimetidine is a high soluble, low permeable histamine H2 receptor antagonist. For instance, during the development of cimetidine, permeability-enhancing strategies (e.g. increase in carrier-mediated transport) have been studied, although these approaches are often challenging to realise, and can lead to problems with toxicity. The bioavailability of cimetidine is dependent on the activity of carriers in the GI tract and interactions with other agents. Due to the fact that permeability has had an important impact on bioavailability and dissolution tests conducted in vitro do not always correlate with dissolution results in vivo, cimetidine is usually not suitable for biodegradation studies.

BCS Class IV: Ritonavir: Ritonavir is an HIV protease inhibitor with low solubility and low permeability. Innovative formulation strategies (e.g.,

nanotechnology-based systems, liposomes) have been used in the development of ritonavir to simultaneously increase solubility and permeability. The bioavailability of ritonavir can vary significantly depending on the type of formulation, particle size, solubility, permeability, and activity of efflux carriers. Biodegradation studies are generally not suitable for ritonavir because both solubility and permeability can affect bioavailability, and in vitro, dissolution tests may not correlate well with in vivo data (Charalabidis, 2019; Cook, 2010).

7.2. Examples of Success and Failure of Bio-Delayed Studies

Success Case: Acetaminophen is a highly soluble and highly permeable (BCS Class I) analgesic and antipyretic drug. Biodegradable studies for acetaminophen have shown that different formulations are bioequivalent, facilitating generic drug development. In vitro dissolution tests correlated well with in vivo data, supporting regulatory acceptance of biodegradable studies (Barzegar-Jalali, 2022).

Failure Example: Digoxin is a cardiac glycoside with a narrow therapeutic index. Digoxin can be classified as BCS Class II or III based on its solubility and permeability properties. Biodegradable studies for digoxin have shown that in vitro dissolution tests do not correlate well with in vivo data in some cases, which has prevented regulatory acceptance of biodegradable studies. The narrow therapeutic index of digoxin means that even small changes in bioavailability can affect clinical outcomes, and therefore in vivo studies are required to demonstrate bioequivalence (Gona, 2023).

8. Factors to be Considered in BCS Assessment of Microorganisms

Individual microbiota vary greatly between humans, which influences the efficacy of the consumption of probiotics and prebiotics, the use of antibiotics, and drug-microbiota interactions. Microorganisms have an essential part in the evaluation of the BCS. Microbiota composition is personalized therefore it can alter drug absorption in different individuals. Any BCS studies must account for this heterogeneity. Furthermore, microbiota-modulating effects of prebiotics and probiotics can affect the permeability and solubility of drugs in the microbiota, which is also crucial for BCS analysis. Moreover, alterations in microbial composition as a result of antibiotic administration can result in changed profiles of drug absorption, and thus it is vital to take BCS findings into consideration in patients receiving antibiotics (Yarahmadi, 2024; Schupack, 2022).

Overall, integrated in vitro and in vivo approaches that complement each other are needed in order to expand knowledge of drug-drug interactions and improve the predictive power of BCS estimations.

Conclusion

Role of BCS in the Development and Formulation of Cancer Drugs The Biopharmaceutical Classification System (BCS) gives input on formulation strategies by identifying significant characteristics of the drug that dictate absorption. Nonetheless, the impact of microorganisms existing within the gastrointestinal tract on drug solubility, permeability and metabolism are often overlooked. This is essential for enhancing the bioavailability and efficacy of cancer drugs due to the influence of microorganisms on BCS evaluations. Further research will help us to characterize the drug-microbiota relationship and incorporate them into therapeutic approaches. This provides the basis for creating personalized treatment strategies and obtaining more effective cancer treatment outcomes.

References

Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: current status and future directions. *Molecules*, 26(19), 5905.

AR, Poonam Irache Jain CM Jaiswal; HP, Irache P. Yelane AH Tattu. A review on solubility enhancement technique for pharmaceutical drugs. *GSC Biological and Pharmaceutical Sciences*, 2024, 26.2: 239.

Arrunátegui, L. B., Silva-Barcellos, N. M., Bellavinha, K. R., Ev, L. D. S., & Souza, J. D. (2015). Biopharmaceutics classification system: importance and inclusion in biowaiver guidance. *Brazilian Journal of Pharmaceutical Sciences*, 51, 143-154.

Avdeef, A., Fuguet, E., Llinàs, A., Ràfols, C., Bosch, E., Völgyi, G., ... & Takács-Novák, K. (2016). Equilibrium solubility measurement of ionizable drugs—consensus recommendations for improving data quality. *Admet and Dmpk*, 4(2), 117-178.

Baral, K. C., & Choi, K. Y. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. *Pharmaceutics*, 17(4), 397.

Baral, K. C., & Choi, K. Y. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. *Pharmaceutics*, 17(4), 397.

Barzegar-Jalali, M., Jafari, P., & Jouyban, A. (2022). Acetaminophen solubility in aqueous solutions of betaine-propylene glycol natural deep eutectic solvent at different temperatures. *Journal of Molecular Liquids*, 349, 118199.

Bennion, B. J., Be, N. A., McNerney, M. W., Lao, V., Carlson, E. M., Valdez, C. A., ... & Carpenter, T. S. (2017). Predicting a drug's membrane permeability: A computational model validated with in vitro permeability assay data. *The journal of physical chemistry B*, 121(20), 5228-5237.

Beran, K., Hermans, E., Holm, R., Sepassi, K., & Dressman, J. (2024). Using the refined Developability Classification System (rDCS) to guide the design of oral formulations. *Journal of Pharmaceutical Sciences*, 113(12), 3497-3517.

Bhalani, D. V., Nutan, B., Kumar, A., & Singh Chandel, A. K. (2022). Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. *Biomedicines*, 10(9), 2055.

Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020). Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. *Advanced drug delivery reviews*, 157, 2-36.

Brunner, J., Ragupathy, S., & Borchard, G. (2021). Target specific tight junction modulators. *Advanced drug delivery reviews*, 171, 266-288.

Chavda, H. V., Patel, C., & Anand, I. (2010). Biopharmaceutics classification system. *Systematic reviews in pharmacy*, 1(1), 62.

Chunduru, J., & Chadalawada, P. (2024). Solid Dispersions As Strategy To Improve Solubility And Dissolution Rate Of Water Insoluble Drugs. *World Journal of Pharmaceutical Research*, 13(19), 329-347.

Cook, J. A., Davit, B. M., & Polli, J. E. (2010). Impact of biopharmaceutics classification system-based biowaivers. *Molecular pharmaceutics*, 7(5), 1539-1544.

Dhake, P. R., Kumbhar, S. T., & Gaikwad, V. L. (2024). Biowaiver based on biopharmaceutics classification system: Considerations and requirements. *Pharmaceutical Science Advances*, 2, 100020.

Díaz-Dinamarca, D. A., Salazar, M. L., Castillo, B. N., Manubens, A., Vasquez, A. E., Salazar, F., & Becker, M. I. (2022). Protein-based adjuvants for vaccines as immunomodulators of the innate and adaptive immune response: Current knowledge, challenges, and future opportunities. *Pharmaceutics*, 14(8), 1671.

Ding, L., Agrawal, P., Singh, S. K., Chhonker, Y. S., Sun, J., & Murry, D. J. (2024). Polymer-based drug delivery systems for cancer therapeutics. *Polymers*, 16(6), 843.

Ebert, A., Dahley, C., & Goss, K. U. (2024). Pitfalls in evaluating permeability experiments with Caco-2/MDCK cell monolayers. *European Journal of Pharmaceutical Sciences*, 194, 106699.

Elumalai, K., Srinivasan, S., & Shanmugam, A. (2024). Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. *Biomedical Technology*, 5, 109-122.

Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., ... & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. *Helijon*, 9(6).

Fedi, A., Vitale, C., Ponschin, G., Ayehunie, S., Fato, M., & Scaglione, S. (2021). In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: A systematic review. *Journal of Controlled Release*, 335, 247-268.

Giordani, S., Marassi, V., Zattoni, A., Roda, B., & Reschiglian, P. (2023). Liposomes characterization for market approval as pharmaceutical products: Analytical methods, guidelines and standardized protocols. *Journal of pharmaceutical and biomedical analysis*, 236, 115751.

Gona, S. R., Rosenberg, J., Fyffe-Freil, R. C., Kozakiewicz, J. M., & Money, M. E. (2023). Failure of current digoxin monitoring for toxicity: new monitoring recommendations to maintain therapeutic levels for efficacy. *Frontiers in Cardiovascular Medicine*, 10, 1179892.

Guideline, I. H. (2019). Biopharmaceutics classification system-based biowaivers M9. *Int. Counc. Harmon. Tech. Requir. Pharm. Hum. Use*.

Guideline, I. H. (2019). Biopharmaceutics classification system-based biowaivers M9. *Int. Counc. Harmon. Tech. Requir. Pharm. Hum. Use*.

Gupta, D., Bhatia, D., Dave, V., Sutariya, V., & Varghese Gupta, S. (2018). Salts of therapeutic agents: chemical, physicochemical, and biological considerations. *Molecules*, 23(7), 1719.

Jorgensen, C., Linville, R. M., Galea, I., Lambden, E., Vögele, M., Chen, C., ... & Lorenz, C. D. (2025). Permeability benchmarking: guidelines for comparing in silico, in vitro, and in vivo measurements. *Journal of Chemical Information and Modeling*.

Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024). Unveiling the mechanisms and challenges of cancer drug resistance. *Cell Communication and Signaling*, 22(1), 109.

Kim, T. H., Paik, S. H., Chi, Y. H., Bulitta, J. B., Lee, D. Y., Lim, J. Y., ... & Shin, B. S. (2018). Regional absorption of fimasartan in the gastrointestinal tract by an improved in situ absorption method in rats. *Pharmaceutics*, 10(4), 174.

Kozolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., ... & Corsetti, M. (2019). The mechanisms of pharmacokinetic food-drug interactions—A perspective from the UNGAP group. *European Journal of Pharmaceutical Sciences*, 134, 31-59.

Ku, M. S., & Dulin, W. (2012). A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. *Pharmaceutical development and technology*, 17(3), 285-302.

Kus, M., Ibragimow, I., & Piotrowska-Kempisty, H. (2023). Caco-2 cell line standardization with pharmaceutical requirements and in vitro model suitability for permeability assays. *Pharmaceutics*, 15(11), 2523.

Lange, J. J., Enzner, L., Kuentz, M., O'Dwyer, P. J., Saal, W., Griffin, B. T., & Wytttenbach, N. (2025). Exploration of solubilisation effects facilitated by the combination of Soluplus® with ionic surfactants. *European Journal of Pharmaceutical Sciences*, 205, 106957.

Lodhi, D. S., Panwar, A. S., & Dongre, N. (2022). Review study on analysis of the solubility of biopharmaceutical classification system class ii drugs in a self-emulsifying drug delivery system. *Asian J Pharm Clin Res*, 15(2), 36-45.

Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023). Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. *ACS Materials Au*, 3(6), 600-619.

Metry, M., & Polli, J. E. (2022). Evaluation of excipient risk in BCS class I and III bio waivers. *The AAPS journal*, 24(1), 20.

Metry, M., & Polli, J. E. (2022). Evaluation of excipient risk in BCS class I and III bio waivers. *The AAPS journal*, 24(1), 20.

Miranda, C., Aceituno, A., Fernández, M., Mendes, G., Rodríguez, Y., Llauró, V., & Cabrera-Pérez, M. Á. (2021). ICH guideline for biopharmaceutics classification system-based bio waiver (M9): Toward harmonization in Latin American countries. *Pharmaceutics*, 13(3), 363.

Neaz, S., Alam, M. M., & Imran, A. B. (2024). Advancements in cyclodextrin-based controlled drug delivery: Insights into pharmacokinetic and pharmacodynamic profiles. *Heliyon*, 10(21).

Newman, A., Hastedt, J. E., & Yazdanian, M. (2017). New directions in pharmaceutical amorphous materials and amorphous solid dispersions, a tribute to Professor George Zografi—Proceedings of the June 2016 Land O'Lakes Conference. *AAPS Open*, 3(1), 7.

O'Shea, J. P., Augustijns, P., Brandl, M., Brayden, D. J., Brouwers, J., Griffin, B. T., ... & O'Driscoll, C. M. (2022). Best practices in current models mimicking drug permeability in the gastrointestinal tract-An UNGAP review. *European Journal of Pharmaceutical Sciences*, 170, 106098.

Panwar, A. S. (2021). A review on solubility enhancement of Biopharmaceutical Classification System Class II drugs using bilayer tablet technology. *International Journal of Green Pharmacy (IJGP)*, 15(2).

Pawar, B., Vasdev, N., Gupta, T., Mhatre, M., More, A., Anup, N., & Tekade, R. K. (2022). Current update on transcellular brain drug delivery. *Pharmaceutics*, 14(12), 2719.

Rangaraj, N., Sampathi, S., Junnuthula, V., Kolimi, P., Mandati, P., Narala, S., ... & Dyawanapelly, S. (2022). Fast-fed variability: insights into drug delivery, molecular manifestations, and regulatory aspects. *Pharmaceutics*, 14(9), 1807.

Samineni, R., Chimakurthy, J., & Konidala, S. (2022). Emerging role of biopharmaceutical classification and biopharmaceutical drug disposition

system in dosage form development: A systematic review. *Turkish journal of pharmaceutical sciences*, 19(6), 706.

Schupack, D. A., Mars, R. A., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022). The promise of the gut microbiome as part of individualized treatment strategies. *Nature reviews Gastroenterology & hepatology*, 19(1), 7-25.